Di Marino M, S29
Dieleman JP, 411
Dimitri É, 348
Dinkel JJ, 32
Donahue SR, 235
Dorado P, 352
Doruk A, 467
Dowling BP, 596
Doyle R, 479
Drieling T, 555
Dunn J, 587
Durcan MJ, 667

E

Ebinger M, 105
Edwards SE, 392
Eide CE, 710
Eisfeld BS, 107
Ekman A, 195
Elbaz Z, 59
Flanagan L, 59
Elgamal S, 357
Emsley R, 210
Engh JA, 132
Eriksson E, 195
Eudicone J, 243
Evert M, 254
Evins AE, 660
Eyler LT, 225

F

Fagiolini A, 257
Fallon BA, 638
Fan CC, 473
Fan J, 59
Fangmann P, 1
Fankhauser M, 646
Farabaugh A, 660
Færden A, 132
Farré M, 525
Fava M, 156, 660
Fazel S, 477
Fehr C, 317
Fellows C, 608
Feng X-J, 264
Fergusson D, 467
Ferranti J, 472
Ferris LE, 230
Findling RL, 441
Fitzgerald PB, 52
Fleck JR, 302
Fletcher PJ, 494
Flynn J, 354
Folnegović-Šmalc V, 713
Fong CYS, 110
Forbes RA, 441
Fothergill A, 714
Frank E, 257
Frankhauser P, 581
Franklin DL, 470
Freeman MP, 646
Freitas MCS, 592
Freudenmann RW, 500
Fried K, 646
Friedel RO, 345
Friedman JI, 59
Friis S, 132
Frye MA, 243
Fukuda T, 518
Fukui N, 325
Fulgosi MC, 249
Fulton K, 329
Fusar-Poli P, 484

G

Gajwani P, 203
Gann H, 317
Ganocy SJ, 203
Gao K, 203
Garcia-Espana F, 447
García-Gea C, 675
Garcia-Unzueta MT, 289
Gardner KF, 532
Gastpar M, 593
Gau C-S, 271, 509
Gau SS-F, 271, 247, 340, 584
Geracioti Jr. TD, 596
Ghanizadeh A, 725
Ghodse AH, 114
Giacca A, 494
Gibel A, 456
Gigli GL, 654
Gilles M, 581
Glass JR, 182
Glick ID, 96
Goggins WB, 110
González CA, 1
Goodwin G, 477
Goodwin RS, 432
Gorelick DA, 432
Gosnell BA, 21
Gramigna GD, 532
Grann M, 477
Greenblatt DJ, 369
Gregoriou S, 219
Grugno R, 589
Gründer G, 608
Grunze H, 555
Guerra de Andrade A, 252
Gulsun M, 467

H

Haburchak D, 455
Haight BR, 302
Hake L, 572
Hallert C, 424
Hamidovic A, 45
Hamilton J, S20
Han C, 117
Han J, 5
Hara C, 578
Hardisty R, 476
Harvey M, 221
Harvey PD, 59
Hawe R, 454
Hayes RJ, 432
Heinz A, 452
Heise Jr. RH, 714
Hennicken D, 156
Hennig-Fast K, 669
Herring S, 52
Herrmann N, 182, 296
Heuser I, 474
Hiemke C, 608
Ho CS, 110
Ho PC, 110
Hofman A, 411
Hohagen F, 550
Hooper-Wood C, 117
Hosoi Y, 518
Horvath A, 705
Houck PR, 257
Hoy K, 52
Huang C-H, 64
Hung CH, 727
Huang C-L, 64
Huang MC, 473
Huang M-C, 726
Huestis MA, 432
Huguelet P, 102
Hui E, 110
Hunt T, 302
Huston CS, 345
Hwang MY, 349

I

Inoue Y, 325
Ip SP, 110
Iyer GR, 235

J

Jackson WT, 345
Jakob F, 474
Jakovljević M, 713
Jamal MM, 462
Janes F, 654
Janowsky DS, 401
Jeenah FY, 93
Jefferson JW, 96
Jeong SH, 618
Jeste DV, 225
Joe S-H, 375
Johnsen E, 686
Johnson MC, 302
Jonas A, 13
Jonsdottir H, 132
Jonsson GW, 93
Janouschek H, 608
Joshi KG, 354
Jørgensen HA, 686
Juckel G, 1
Jung DC, 618
Jung H-G, 375
Jung S-W, 375
Jurik J, 221
Juurlink DN, 230

K

Kahl KG, 550
Källén B, 279
Kagerer S, 699
Kalali AH, S20
Kane JM, S29, 691
Kang D-H, 108
Kang S-G, 711
Kang UJ, 45
Kauffman RE, 441
Karagiorga T, 219
Karakatsanis NA, 104
Karapoulios E, 104
Kashima H, 540
Kato M, 518
Katona C, 32
Katz MM, 468
Kauffman M, 235
Keijzer L, 570
Kelly DL, 353
Kelmendi B, 363
Kemp DE, 203
Kennedy A, 74, 221
Kennedy SH, 107, 329
Keulen J-THA, 78
Khalid AS, 401
Khan A, 13
Kikuchi T, 540
Kilzieh N, 74, 221
Kim E, 138
Kim JH, 618
Kim J-J, 138
Kim J-M, 349
Kim S-W, 349
Kim S-W, 618
Kim YS, 618
Kinon BJ, 392, 544, 601
Kinoshita T, 518

© 2008 Lippincott Williams & Wilkins

Kirby NL, 345
Kirchheiner J, 78
Kobak KA, 691
Ko Y-H, 375
Koch N, 550
Koen L, 210
Kolbrich EA, 432
Kollack-Walker S, 601
Koller G, 317, 699
Kolluri S, 631
Konopelska S, 120
Kontoangelos K, 251, 362
Kontochristopoulos G, 219
Kopf D, 581
Kordon A, 550
Koschke M, 694
Kotler ML, 667
Koulouris G, 362
Kouraichi N, 241
Kouvelas D, 579
Kouvelou E, 579
Kouzoupis AV, 104, 251, 362
Kozumplik O, 713
Krakowski MI, 485
Krams M, 631
Kranzler H, 5
Krishen A, 302
Kroken RA, 686
Kruger THC, 705
Kuefner H, 699
Kulkarni J, 52
Kupfer DJ, 257
Kupsch A, 452
Kwok T, 110
Kwon JS, 108

L

Laan W, 214
Lai CYL, 110
Lam C, 494
Lam CWK, 110
Lam L, 110
Lam L, 494
Lanctôt KL, 296
Landen JW, 631
Landry P, 348, 706
Landvogt C, 608
Lane H-Y, 64, 576
Lang TR, 714
Langosch JM, 555, 567
Lara DR, 595
Laska E, S29
Lauriello J, S29
Leamon MH, 472
Lebowitz BD, 225
Lederbogen F, 581
Lee C-H, 375
Lee E, 707
Lee H-J, 711
Lee J, 536
Lee K-J, 711
Lee KY, 618
Lee M-S, 375
Lee S-H, 711
Légaré N, 348
Lehnert P, 699
Lemmonds CA, 667
Lépine J-P, 570
Lepping P, 500
Lesch O-M, 317
Leslie WD, 384
Leung C-M, 707
Leung V, 110
Lew Y-M, 375
Leweke M, 317
Lieb M, 699
Lieberman JA, 392
Liebowitz MR, 638
Liese BS, 660
Limmer C, 699
Lin C-C, 591
Lin S-K, 189
Lin SK, 473
Lin WK, 727
Lin Y-C, 576
Lin Y-J, 509
Lindenmayer J-P, 392
Linszen D, 214
Liskow BI, 101
Litman RE, S4
Liu BA, 296
Liu R-M, 264
Liu Y-C, 64
Liu-Seifert H, 392
Lix L, 384
Llerena A, 352
Loew TH, 355
Lofgreen C, 221
Löfgren U-B, 424
López-Muñoz F, 1
López-Torres E, 352
Lorenzi C, 249
Lu BY, 710
Lu J, 59
Lui V, 110
Lyon GJ, 720

M

Maayan R, 456
MacQueen G, 357
Maguire GA, 470
Malfertheiner P, 254
Mall GD, 572
Malla A, 69
Mallikaarjun S, 441
Malte C, 221
Maluf S, 525
Manchanda R, 69
Mandos LA, 447
Manki H, 540
Mann KF, 317
Mann SW, 494
Mannelli P, 117
Marcus RN, 5, 13, 156, 243
Marcus SC, 255
Markowitz JS, S37, S54
Martínez-Colomer J, 675
Masand PS, 117
Masdrakis VG, 104, 251, 362
Mata I, 289
Mathew S, 235
Matsoukas T, 362
Mattson U-B, 195
May RS, 345
Mazurek MF, 459
McEvoy JP, 392
McGlinchey RE, 532
McKenna P, 248
McQuade RD, 13, 156, 243
McQueen S, 52
McRae AL, 464
Mech AW, 240
Medori R, 210
Meltzer HY, 392
Menniti FS, 631
Merkl A, 474
Metge C, 384
Meyer F, 722
Miller D, 118
Mintz J, 462
Mitchell JE, 21
Modell JG, 302
Moher D, 467
Mok H, 110
Mok V, 110
Moleman P, 166, 717
Mônica MD, 252
Montejo AL, 568
Moore DJ, 225
Moore KM, 714
Moosa MY, 93
Moreno F, 646
Mulder PG, 166
Müller-Bock V, 258
Mundo E, 406
Murad Jr. M, 578

N

Nakajima S, 540
Naudts K, 147
Neumann H, 254
Ng B, 116
Ng C, 110
Nickel MK, 355
Nickel T, 105
Niehaus DJH, 210
Nissbrandt H, 195
Nobrega JN, 494
Nolan KA, 485
Nolan Jr. PE, 646
Nomura K, 540
Nonen S, 518
Nyhuis PW, 593
Nyilas M, 441

O

O'Mathúna B, 525
Okugawa G, 518
Olberg H, 686
Olfson M, 255
Onken V, 581
Ono S, 325
Oosthuizen PP, 210
Opjordsmoen S, 132
Oshana S, 235
Oulis P, 104, 251, 362
Ouyang W-C, 576
Owen R, 13
Oyefeso A, 114
Ozdemir V, 325, 462

P

Pachou E, 251
Pae C-U, 117
Palmer BW, 225
Pan C-H, 189, 726
Papadimitriou GN, 362
Papazisis G, 579
Pardo R, 525
Parikh AR, 101
Park D-W, 138
Park Y-M, 711
Parrella M, 59
Parsons Jr. EC, 235
Patkar AA, 117
Patrick KS, S37, S54
Patterson TL, 225
Pava J, 660
Pavlovic ZM, 119
Peindl K, 117
Pelayo-Terán JM, 289
Pelizza L, 709
Peng P-W, 726
Peñas-LLedó E, 352
Perez-Iglesias R, 289
Perkins KA, 247
Perroud N, 102
Peselow ED, 96
Petkova E, 638

© 2008 Lippincott Williams & Wilkins

Petty F, 84
Piani A, 654
Pikalov A, 243, 441
Pittenger C, 363
Polimeni G, 589
Pollack MH, 308
Pols HAP, 411
Pomarol E, 248
Pontiggia A, 249
Poon L-Y, 536
Postma MJ, 625
Potkin SG, S1, S4
Pourzitaki C, 579
Prakash O, 359
Preskorn SH, 631
Prince J, S39
Prior H, 384

Q

Quante A, 474
Quinkler M, 120
Quinn D, S62

R

Rabinowitz J, 210
Radaelli D, 249
Ramos MG, 578
Raskin J, 32
Rasmussen J, 329
Rauh S, 258
Ravindran LN, 107
Reinhard Jr. JF, 235
Reis M, 279
Reist C, 462
Relecom C, 102
Remington G, 494
Richards C, 459
Rickels K, 235, 447
Rico-Villademoros F, 568
Rifkin AE, 367
Rigopoulos D, 219
Riley GD, 470
Rinaldi A, 654
Ringen PA, 132
Ritsner MS, 456
Rizvi S, 329
Rocha FL, 578
Roerig JL, 21
Roots I, 78
Rosebush PI, 459
Rosenhagen MC, 105
Rostami-Hodjegan A, 525
Rösch F, 200674
Rothenburg LS, 296
Rudolph JL, 532
Ryan M, 296

S

Sacco KA, 340, 584
Saddichha S, 27
Safarinejad MR, 39, 418
Salkeld E, 230
Sallee FR, 441
Salomón J, 352
Salzman C, 96
Sanchez-Lacay A, 638
Santos Filho A, 592
Sareen J, 384
Sasse J, 555
Savas HA, 360
Sawamura K, 325
Saxon AJ, 221
Schäfer W, 608
Scherbaum N, 593
Schieldrop P, 69
Schifano F, 114
Schilling C, 581
Schneier F, 638
Schnieber M, 705
Schlachetzki JCM, 567
Schmidt P, 317
Schmidt U, 105
Schommer NC, 474
Schulz S, 694
Segrave R, 52
Senturk V, 147
Sevincok L, 573
Shader RI, 261, 599
Shafti SS, 718
Shahveisi B, 718
Shen J, 691
Shim GS, 108
Shim J-C, 353
Shin I-S, 349
Shoaf SE, 441
Shults J, 171
Shur-Fen Gau S, 509
Shytle RD, 340
Simon JS, 156
Sinclair S, 195
Skritskaya N, 638
Smeraldi E, 249
Sniadecki J, 601
Soldatos CR, 104, 251
Someya T, 325
Soreca I, 257
Sörvik K, 195
Soyka M, 317, 699
Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction, 568
Spreckelmeyer K, 608
Sproule BA, 182
Stahl S, 96
Stauffer V, 392
Stauffer VL, 601
Steffen KJ, 21
Stein DJ, 561
Stein EA, 432
Stewart JT, 361
Stolk RP, 625
Stoves A, 345
Strasburger CJ, 120
Stratigos A, 219
Strawn JR, 596
Ströhle A, 452
Sugiyama E, 721
Sugiyama N, 721
Stricker BHCh, 411
Strous RD, 456
Su H-K, 576
Sugai T, 325
Suzuki T, 540
Suzuki Y, 325
Szabo S, 462
Sze CW, 264
Szeto S, 110

T

Takekita Y, 518
Takeuchi H, 540
Tamano EA, 101
Tan Q-R, 264
Tancer M, 694
Tang CY, 59
Tapp A, 221
Tapp AM, 74
Targum SD, 118, 587
Tessier S, 348
Thabet H, 241
Thas O, 147
Thase ME, 13, 156, 302, 368
Thatcher BT, 101
Theoharides TC, 479
Tiller J, 308
Tirosh E, 89
Todd-Stenberg JA, 74
Tolliver BK, 464
Tong Y, 264
Tonia T, 114
Torrens M, 525
Torres R, S4
Tran NL, 470
Trivedi MH, 156, 308
Tsai C-J, 726
Tsai GE, 64
Tsoh J, 110
Tucker GT, 525

U

Uchida H, 540
Urbano MR, 704
Uhr M, 105
Uzun S, 713

V

Valente M, 654
Valiente R, 675
van Beveren N, 214
Van Den Berg PB, 625
van den Brink W, 214
van den Broek WW, 166, 717
Van den Eynde F, 147
van der Cammen TJM, 411
van Heeringen C, 147
van Nimwegen L, 214
Varkula M, 245
Vazquez-Barquero JL, 289
Vehof J, 625
Ventz M, 120
Verduin ML, 464
Vermes D, 638
Vernaleken I, 608
Veselinovic T, 608
Vessicchio JC, 340, 584
Vicario F, 352
Vielhaber K, 550
Virit O, 360
Vitetta A, 589
Voderholzer U, 550
Vogels C, 147
Volavka J, 392
Volonakis K, 219
von Wietersheim J, 258
Vorspan F, 570
Voss A, 694

W

Wagner KD, 96
Wahl K, 550
Wakeno M, 518
Walden J, 555
Walker DJ, 32
Wan GJ, 255
Wang C-Y, 264
Ward LC, 84
Ware JC, 704
Wasylink S, 363
Watanabe J, 325
Watanabe K, 540
Waters BM, 354
Watson WJ, 714
Weber-Hamann B, 581
Weiden PJ, S12, S20
Weinberger AH, 247, 340, 584

© 2008 Lippincott Williams & Wilkins

Weizman A, 456
White L, 59
Wichman CL, 580, 714
Wilens TE, S46
Williams CC, 710
Williams R, 69
Wilson DR, 392
Wiltse CG, 32
Winter C, 452
Wolfgang CD, S4, S12, S20, S29
Wong A, 110
Wong DF, 608
Woo J, 110
Wood AE, 74, 221
Woosley RL, 646
Wu P-L, 64
Wu X, 13

X

Xia G, 203
Xie F, 308
Xiong GL, 472

Y

Yamashita M, 518
Yang J, 525
Yang S-J, 349
Yeragani VK, 694
Yeung W-S, 113
Yokoyama S, 721
Yoon CK, 574
Yoon J-S, 349
You Y-S, 353
Ysander C, 195
Yu XW, 110
Yuan H-N, 264

Z

Zanchettin B, 654
Zanoni S, 406
Zee BC-Y, 110
Zhang HF, 255
Zhang J-Z, 264
Zhang Y-B, 264
Zhang Z-J, 264
Zhao Y, 691
Ziere G, 411
Zimbroff DL, 235
Zingg C, 699
Zisook S, 96
Zuardi AW, 592
Zoroglu S, 723
Zurowski B, 550

© 2008 Lippincott Williams & Wilkins

Subject Index

A

5-HTTLPR
Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation (letter). Benedetti, April, 249

5-Hydroxytryptamine (5-HT)
Successful treatment of nicotine withdrawal with duloxetine: A case report (letter). Perroud, Feb, 102

A–α-1 Antichymotrypsin
Neuroleptic malignant syndrome and the acute phase response (letter). Rosebush, Aug, 459

Abilify, *see* **Aripiprazole**

Acetaminophen
Association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: A nested matched case-control study. Gau, Oct, 509

Acetylcholinesterase inhibitor (AChEI)
Galantamine as an adjunctive treatment in major depression (letter). Elgamal, June, 357

Acute angle-closure glaucoma
Dose-related increase of intraocular pressure caused by venlafaxine use: Case report (letter). Della Mônica, April, 252

Acute dystonia
Acute dystonic reaction after initiating aripiprazole monotherapy in a 20-year-old man (letter). Varkula, April, 245

Acute mania, *see* **Mania**

Acute phase response
Neuroleptic malignant syndrome and the acute phase response (letter). Rosebush, Aug, 459

Addiction
Alleviation of both binge eating and sexual dysfunction with naltrexone (letter). Meyer, Dec, 722
An open-label study of aripiprazole in nonschizophrenic crack-dependent patients (letter). Vorspan, Oct, 570

Addiction Research Center Inventory (ARCI)
Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. Hamidovic, Feb, 45

Adenosine monophosphate–activated protein kinase (AMPK)
A preliminary investigation of α-lipoic acid treatment of antipsychotic drug–induced weight gain in patients with schizophrenia. Kim, April, 138

ADHD, *see* **Attention–deficit/hyperactivity disorder (ADHD)**

Adiponectin
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289

Adolescents
Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders (brief report): An open-label, dose-escalation study. Findling, Aug, 441

Adults
A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. Evins, Dec, 660
Acute psychosis induced by clarithromycin in a healthy adult? (letter). Kouvelou, Oct, 579
Antipsychotic withdrawal–induced relapse predicts future relapses in institutionalized adults with severe intellectual disability. Janowsky, Aug, 401
Tiagabine in adult patients with generalized anxiety disorder: Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. Pollack, June, 308

Adverse drug events (ADEs), *see also* **Adverse drug reactions (ADRs); Adverse events (AEs)**
A 2-year prospective follow-up study of lower urinary tract symptoms in patients treated with clozapine. Jeong, Dec, 618
A preliminary investigation of α-lipoic acid treatment of antipsychotic drug–induced weight gain in patients with schizophrenia. Kim, April, 138
Dose-related increase of intraocular pressure caused by venlafaxine use: Case report (letter). Della Mônica, April, 252
Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: A population-based study. Cancelli, Dec, 654
Leukopenia during therapy with risperidone long-acting injectable: Two case reports (letter). Uzun, Dec, 713
Myoclonus provoked by lamotrigine in a bipolar patient (letter). Corcuera, April, 248

Adverse drug reactions (ADRs), *see also* **Adverse drug events (ADEs)**
Beyond the "Hype" on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use (guest editorial). de Leon, April, 125
Duloxetine-induced cutaneous adverse reaction (letter). Oulis, Feb, 104
The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: A nested matched case-control study. Gau, Oct, 509

Toxic epidermal necrolysis and fluoxetine: A case report (brief report). Jonsson, Feb, 93

Adverse events (AEs), *see also* **Adverse drug events (ADEs); Adverse drug reactions (ADRs)**
Acute psychosis induced by clarithromycin in a healthy adult? (letter). Kouvelou, Oct, 579
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR (brief report). Kennedy, June, 329
Assessment of the prescription of antidepressant drugs in elderly nursing home patients: A clinical and laboratory follow-up investigation. Chermá, Aug, 424
Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial. Soyka, June, 317
Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Potkin, April, S4
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Cutler, April, S20
Long-acting risperidone–induced periorbital edema (letter). Pelizza, Dec, 709
Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29
Methylphenidate for the treatment of apathy in Alzheimer disease: Prediction of response using dextroamphetamine challenge. Herrmann, June, 296
Preparation of scientific reports on pharmacokinetic drug interaction studies (editorial). Greenblatt, Aug, 369
Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. Weiden, April, S12
Tiagabine in adult patients with generalized anxiety disorder: Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. Pollack, June, 308
Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: An open-label, dose-escalation study (brief report). Findling, Aug, 441

Adverse metabolic effects
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: A case series (letter). Tolliver, Aug, 464

Aggression
Antipsychotic withdrawal–induced relapse predicts future relapses in institutionalized adults with severe intellectual disability. Janowsky, Aug, 401
Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: Young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials (letter). Frye, April, 243
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Krakowski, Oct, 485
Augmentation of clozapine's antiagressive properties with lamotrigine in a patient with chronic disorganized schizophrenia (letter). Pavlovic, Feb, 119
Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. Van den Eynde, April, 147

Aging/Aged
Antipsychotics and oropharyngeal dysphagia in hospitalized older patients (brief report). Rudolph, Oct, 532
Assessment of medication management ability in middle-aged and older adults with bipolar disorder (brief report). Depp, April, 225
Assessment of the prescription of antidepressant drugs in elderly nursing home patients: A clinical and laboratory follow-up investigation. Chermá, Aug, 424
Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: A population-based study. Cancelli, Dec, 654
Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: A randomized, placebo-controlled trial. Glass, April, 182
Fracture risk from psychotropic medications: A population-based analysis. Bolton, Aug, 384
Nonfatal suicidal olanzapine intoxication: A case report (letter). Ramos, Oct, 578
Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. Raskin, Feb, 32
Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. Ziere, Aug, 411

Agitation
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Kinon, Dec, 601

Agomelatine
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR (brief report). Kennedy, June, 329
Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study (brief report). Stein, Oct, 561

Akathisia
Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies. Thase, Feb, 13
Aripiprazole treatment causes extrapyramidal side effects but not

© 2008 Lippincott Williams & Wilkins

prolactin elevation: A disconnect of the striatal D_2 occupancy story: Case report (letter). Shim, June, 353
Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Potkin, April, S4
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Cutler, April, S20
Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29
Mirtazapine-induced akathisia (letter). Gulsun, Aug, 467
Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia (brief report). Cortese, Feb, 69
Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. Weiden, April, S12

Alcoholism
A randomized, multicenter, double-blind, placebo-controlled study of efficacy and safety of aripiprazole for the treatment of alcohol dependence. Anton, Feb, 5
Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence. Soyka, June, 317
Successful treatment of nicotine withdrawal with duloxetine: A case report (letter). Perroud, Feb, 102

A-lipoic acid (ALA)
A preliminary investigation of α-lipoic acid treatment of antipsychotic drug–induced weight gain in patients with schizophrenia. Kim, April, 138

Alpha 2A-adrenergic receptor
The Alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Wakeno, Oct, 518

Alzheimer disease (AD)
Methylphenidate for the treatment of apathy in Alzheimer disease: Prediction of response using dextroamphetamine challenge. Herrmann, June, 296
Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease (letter). Baum, Feb, 110

Amisulpride
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: An open-label switch study (letter). Kim, June, 349
Tardive dystonia associated with low-dose of amisulpride: A case report (letter). Sevincok, Oct, 573

Amphetamine
A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia (brief report). Friedman, Feb, 59

Anorexia nervosa
Five female cases of prolonged depression in chronic anorexia nervosa treated with selective estrogen receptor modulator raloxifene-augmented therapy (letter). Yokoyama, Dec, 721

Antenatal depression
The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants (brief report). Salkeld, April, 230

Antibiomania
Acute psychosis induced by clarithromycin in a healthy adult? (letter). Kouvelou, Oct, 579

Anticholinergic (ACH) drugs
Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: A population-based study. Cancelli, Dec, 654

Anticonvulsants
Divalproex in the treatment of posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial in a veteran population (brief report). Davis, Feb, 84
Maternal use of antipsychotics in early pregnancy and delivery outcome. Reis, June, 279
The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: A nested matched case-control study. Gau, Oct, 509
Water, water everywhere: But is it safe to drink? Return to a muddy topic (editorial). Shader, June, 261

Antidepressants
A case of venlafaxine-induced galactorrhea? (letter). Wichman, Oct, 580
A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy (brief report). Boucher, June, 334
An innovative design to establish proof of concept of the antidepressant effects of NR2B subunit selective *N*-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Preskorn, Dec, 631
Antidepressant-induced sweating alleviated by aripiprazole (letter). Lu, Dec, 710
Assessment of the prescription of antidepressant drugs in elderly nursing home patients: A clinical and laboratory follow-up investigation. Chermá, Aug, 424
Clinical trials of antidepressants: Time to shift to a new model (letter). Katz, Aug, 468
Comments on article by Dr Birkenhager et al "Efficacy of imipramine in psychotic versus nonpsychotic depression" (letter). Baldessarini, Dec, 716
Concentration-response relationship for fluvoxamine using remission as an endpoint: A receiver operating characteristics curve analysis in major depression (brief report). Suzuki, June, 325
Efficacy of imipramine in psychotic versus nonpsychotic depression. Birkenhager, April, 166

© 2008 Lippincott Williams & Wilkins

Five female cases of prolonged depression in chronic anorexia nervosa treated with selective estrogen receptor modulator raloxifene-augmented therapy (letter). Yokoyama, Dec, 721
Fracture risk from psychotropic medications: A population-based analysis. Bolton, Aug, 384
Half a century of antidepressant drugs: On the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: Tricyclics and tetracyclics (guest editorial). Fangmann, Feb, 1
Impact of study design on the results of continuation studies of antidepressants (letter). Deshauer, Aug, 467
Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine (letter). Weber-Hamann, Oct, 581
Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation (letter). Benedetti, April, 249
Mirtazapine-induced akathisia (letter). Gulsun, Aug, 467
Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy (letter). Nyhuis, Oct, 593
Physician Withdrawal Checklist (PWC-20) (brief report). Rickels, Aug, 447
Reply to comments by Mr Carlin and Mr Hardisty (reply). Fazel, Aug, 477
Reply to Dr Baldesssarini's comments on "Efficacy of imipramine in psychotic versus nonpsychotic depression" (reply). Birkenhager, Dec, 717
Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. Ziere, Aug, 411
SSRI-induced violent suicide: Does forensic toxicology hold the answer? (letter). Carlin Jr, Aug, 476
Successful treatment of nicotine withdrawal with duloxetine: A case report (letter). Perroud, Feb, 102
Suicidal ideation associated with duloxetine use: A case series (letter). Parikh, Feb, 101
The Alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Wakeno, Oct, 518
The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants (brief report). Salkeld, April, 230
Toxic epidermal necrolysis and fluoxetine: A case report (brief report). Jonsson, Feb, 93
Ultrahigh frequency repetitive transcranial magnetic stimulation in unipolar depression (letter). Jakob, Aug, 474
Visual and coenesthetic hallucinations associated with modafinil (letter). Oulis, April, 251

Antidepressant therapy

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR (brief report). Kennedy, June, 329
Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: A randomized open-label study. Amsterdam, April, 171
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. Marcus, April, 156

Antiepileptic drug

Acute pregabalin reversal of citalopram-induced sexual dysfunction in generalized anxiety disorder (letter). Oulis, June, 362

Antihistamines

Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H_1 antihistamine: A dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. García-Gea, Dec, 675
Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: A randomized, placebo-controlled trial. Glass, April, 182

Antipsychotic drugs

A case of venlafaxine-induced galactorrhea? (letter). Wichman, Oct, 580
A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels. Roerig, Feb, 21
A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. Gau, June, 271
A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia (brief report). Friedman, Feb, 59
A randomized, multicenter, double-blind, placebo-controlled study of efficacy and safety of aripiprazole for the treatment of alcohol dependence. Anton, Feb, 5
A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: Add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering (brief report). Takeuchi, Oct, 540
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics (letter). Kim, June, 349
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review. Gao, April, 203
Antipsychotic-induced hyperprolactinemia: A

© 2008 Lippincott Williams & Wilkins

cross-sectional survey (brief report). Johnsen, Dec, 686
Antipsychotics and oropharyngeal dysphagia in hospitalized older patients (brief report). Rudolph, Oct, 532
Antipsychotic withdrawal–induced relapse predicts future relapses in institutionalized adults with severe intellectual disability. Janowsky, Aug, 401
Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder? (letter). Schlachetzki, Oct, 567
Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms (letter). López-Torres, June, 352
Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies. Thase, Feb, 13
Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: A disconnect of the striatal D_2 occupancy story: Case report (letter). Shim, June, 353
Atypical antipsychotics and metabolic outcomes in Chinese patients: A comparison of olanzapine and risperidone (letter). Lee, Dec, 707
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Krakowski, Oct, 485
Beyond the "Hype" on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use (guest editorial). de Leon, April, 125
Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: Case report (letter). Mall, Oct, 572
Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: A 3-month prospective, observational study (letter). Montejo, Oct, 568
Clozapine-induced pericardial effusion (letter). Dauner, Aug, 455
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. Birkenaes, April, 132
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289
Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Potkin, April, S4
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Cutler, April, S20
Fracture risk from psychotropic medications: A population-based analysis. Bolton, Aug, 384
Hormonal response to dehydroepiandrosterone administration in schizophrenia: Findings from a randomized, double-blind, placebo-controlled, crossover study (letter). Strous, Aug, 456
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study (brief report). Emsley, April, 210
Maternal use of antipsychotics in early pregnancy and delivery outcome. Reis, June, 279
Neuroleptic malignant syndrome and the acute phase response (letter). Rosebush, Aug, 459
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis (brief report). van Nimwegen, April, 214
Olanzapine-associated new-onset atrial fibrillation (letter). Waters, June, 354
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Kinon, Dec, 601
Photo-onycholysis caused by olanzapine and aripiprazole (brief report). Gregoriou, April, 219
Predictors for starting depot administration of risperidone in chronic users of antipsychotics. Vehof, Dec, 625
Predictors of antipsychotic-induced weight gain in first-episode psychosis: Conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Saddichha, Feb, 27
Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia (brief report). Cortese, Feb, 69
Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. Weiden, April, S12
Short-term testosterone augmentation in male schizophrenics: A randomized, double-blind, placebo-controlled trial. Ko, Aug, 375
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study. Kinon, Aug, 392
Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting (brief report). Kilzieh, Feb, 74
Zotepine-induced QTc prolongation (letter). Lin, Oct, 576

Anxiety

Acute pregabalin reversal of citalopram-induced sexual dysfunction in generalized anxiety disorder (letter). Oulis, June, 362

© 2008 Lippincott Williams & Wilkins

Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: Results of a double-blind, placebo-controlled trial (brief report). Rickels, April, 235
Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study (brief report). Stein, Oct, 561
Rater scoring variability in the serial assessment of anxiety symptoms (letter). Targum, Feb, 118
Tiagabine in adult patients with generalized anxiety disorder: Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. Pollack, June, 308
Anxiolytics
Physician Withdrawal Checklist (PWC-20) (brief report). Rickels, Aug, 447
Aripiprazole
A randomized, multicenter, double-blind, placebo-controlled study of efficacy and safety of aripiprazole for the treatment of alcohol dependence. Anton, Feb, 5
A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: Add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering (brief report). Takeuchi, Oct, 540
An open-label study of aripiprazole in nonschizophrenic crack-dependent patients (letter). Vorspan, Oct, 570
Acute dystonic reaction after initiating aripiprazole monotherapy in a 20-year-old man (letter). Varkula, April, 245
Antidepressant-induced sweating alleviated by aripiprazole (letter). Lu, Dec, 710
Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: Young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials (letter). Frye, April, 243
Aripiprazole in a case presenting with Tourette syndrome and obsessive-compulsive disorder (letter). Winter, Aug, 452
Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder? (letter). Schlachetzki, Oct, 567
Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms (letter). López-Torres, June, 352
Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies. Thase, Feb, 13
Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: A disconnect of the striatal D_2 occupancy story: Case report (letter). Shim, June, 353
Case report of aripiprazole for persistent developmental stuttering (letter). Tran, Aug, 470
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Kinon, Dec, 601
Photo-onycholysis caused by olanzapine and aripiprazole (brief report). Gregoriou, April, 219
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: A case series (letter). Tolliver, Aug, 464
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. Marcus, April, 156
Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: An open-label, dose-escalation study (brief report). Findling, Aug, 441
Asia, Southeast
Spontaneous dyskinesia in first-episode psychosis in a Southeast Asian population (brief report). Lee, Oct, 536
Ativan, *see* **Lorazepam**
Atomoxetine
A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia (brief report). Friedman, Feb, 59
Atrial fibrillation
Olanzapine-associated new-onset atrial fibrillation (letter). Waters, June, 354
Attention-deficit/hyperactivity disorder (ADHD)
Catecholamine dysfunction in attention-deficit/hyperactivity disorder: An update. Prince, June, S39
Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: Does chirality matter? Markowitz, June, S54
Does chirality matter? Pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder. Quinn, June, S62
Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. Wilens, June, S46
Insomnia, night terror, and depression related to clonidine in attention-deficit/hyperactivity disorder (letter). Ghanizadeh, Dec, 725
Introduction. Markowitz, June, S37
Stimulant dosing in the community treatment of adult attention-deficit/hyperactivity disorder (letter). Olfson, April, 255
The effects of methylphenidate on word decoding accuracy in boys with attention-deficit/hyperactivity disorder (brief report). Bental, Feb, 89
Atypical antipsychotic drugs
A preliminary investigation of

© 2008 Lippincott Williams & Wilkins

α-lipoic acid treatment of antipsychotic drug–induced weight gain in patients with schizophrenia. Kim, April, 138
Audience response scoring
Confounding influence of extraneous symptoms on Clinical Global Impression ratings for depression (letter). Targum, Oct, 587
Autism spectrum disorders
Autism, gut–blood-brain barrier, and mast cells (guest editorial). Theoharides, Oct, 479
Automated Neuropsychological Assessment Metrics
Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. Hamidovic, Feb, 45

B

Balloon Analog Risk Task (BART)
Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. Hamidovic, Feb, 45
Balter Award
Announcement. Mitchell B. Balter Award Selection, Dec, 607
Barnes Akathisia Scale (BAS)
Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. Weiden, April, S12
Beck Depression Inventory (BDI)
Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy (letter). Nyhuis, Oct, 593
Beck Depression Inventory, Second Edition (BDI-II)
High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes (letter). Mech, April, 240
Bed wetting
Nocturnal enuresis after paroxetine abrupt discontinuation: A case report (letter). Polimeni, Oct, 589
Behavior
Antipsychotic withdrawal–induced relapse predicts future relapses in institutionalized adults with severe intellectual disability. Janowsky, Aug, 401
Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: Young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials (letter). Frye, April, 243
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Krakowski, Oct, 485
Augmentation of clozapine's antiagressive properties with lamotrigine in a patient with chronic disorganized schizophrenia (letter). Pavlovic, Feb, 119
Autism, gut–blood-brain barrier, and mast cells (guest editorial). Theoharides, Oct, 479
Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. Hamidovic, Feb, 45
Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. Van den Eynde, April, 147
Methylphenidate for the treatment of apathy in Alzheimer disease: Prediction of response using dextroamphetamine challenge. Herrmann, June, 296
Benzodiazepines (BZs)
Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: A randomized, placebo-controlled trial. Glass, April, 182
Fracture risk from psychotropic medications: A population-based analysis. Bolton, Aug, 384
Physician Withdrawal Checklist (PWC-20) (brief report). Rickels, Aug, 447
Benztropine
Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: A disconnect of the striatal D_2 occupancy story: Case report (letter). Shim, June, 353
Bilastine
Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H_1 antihistamine: A dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. García-Gea, Dec, 675
Binge eating
Alleviation of both binge eating and sexual dysfunction with naltrexone (letter). Meyer, Dec, 722
Bipolar depression
Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies. Thase, Feb, 13
Comments on "Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (The BOLDER II Study)" by Dr Thase and colleagues (letters). Rifkin, Dawdy, June, 367
Reply to comments by Dr Rifkin and Dr Dawdy (reply). Thase, June, 368
Bipolar disorder (BD)
A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder (letter). Weinberger, Oct, 584
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review. Gao, April, 203
Assessment of medication management ability in middle-aged and older adults with bipolar disorder (brief report). Depp, April, 225
Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type (letter). Weinberger, April, 247
Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate (brief report). Langosch, Oct, 555

© 2008 Lippincott Williams & Wilkins

High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes (letter). Mech, April, 240
Integrating medical and psychiatric care in patients with bipolar disorder (letter). Fagiolini, April, 257
Myoclonus provoked by lamotrigine in a bipolar patient (letter). Corcuera, April, 248
Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder (letter). Urbano, Dec, 704
The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: A nested matched case-control study. Gau, Oct, 509
Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: An open-label, dose-escalation study (brief report). Findling, Aug, 441
Bipolar II major depressive episode
Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: A randomized open-label study. Amsterdam, April, 171
Blood-brain barrier (BBB)
Autism, gut–blood-brain barrier, and mast cells (guest editorial). Theoharides, Oct, 479
Blood pressure
A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. Thase, June, 302
Body mass index (BMI)
A preliminary investigation of α-lipoic acid treatment of antipsychotic drug–induced weight gain in patients with schizophrenia. Kim, April, 138
Beyond the "Hype" on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use (guest editorial). de Leon, April, 125
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. Birkenaes, April, 132
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289
Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine (letter). Weber-Hamann, Oct, 581
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study (brief report). Emsley, April, 210
Predictors of antipsychotic-induced weight gain in first-episode psychosis: Conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Saddichha, Feb, 27
Weight gain and first-generation antipsychotics: Experience from a developing country (letter). Yoon, Oct, 574
BOLDER II Study
Comments on "Efficacy of monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (The BOLDER II Study)" by Dr Thase and colleagues (letters). Rifkin, Dawdy, June, 367
Reply to comments by Dr Rifkin and Dr Dawdy (reply). Thase, June, 368
Bone mineral density
Fracture risk from psychotropic medications: A population-based analysis. Bolton, Aug, 384
Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. Ziere, Aug, 411
Books Received, Dec, 729
Borderline Disorder Rating Scale (BDRS)
Risperidone treatment of borderline personality disorder assessed by a borderline personality disorder–specific outcome measure: A pilot study (letter). Friedel, June, 345
Borderline personality disorder
Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. Van den Eynde, April, 147
Risperidone treatment of borderline personality disorder assessed by a borderline personality disorder–specific outcome measure: A pilot study (letter). Friedel, June, 345
Topiramate treatment of women with borderline personality disorder, part II: An open 18-month follow-up (letter). Loew, June, 355
Varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline depressive disorder and methamphetamine abuse in remission (letter). Lyon, Dec, 720
Brain reward system
Methylphenidate for the treatment of apathy in Alzheimer disease: Prediction of response using dextroamphetamine challenge. Herrmann, June, 296
Brief Psychiatric Rating Scale (BPRS)
A preliminary investigation of α-lipoic acid treatment of antipsychotic drug–induced weight gain in patients with schizophrenia. Kim, April, 138
Assessment of medication management ability in middle-aged and older adults with bipolar disorder (brief report). Depp, April, 225
Brief Substance Craving Scale (BRCS)
Quetiapine for the treatment of cocaine dependence: An open-label

© 2008 Lippincott Williams & Wilkins

trial (brief report). Kennedy, April, 221
Brief Symptom Inventory (BSI)
Risperidone treatment of borderline personality disorder assessed by a borderline personality disorder–specific outcome measure: A pilot study (letter). Friedel, June, 345
Bromocriptine
A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. Yuan, June, 264
Bulimia nervosa
No effect of spironolactone on bulimia nervosa symptoms (letter). von Wietersheim, April, 258
Buprenorphine
Cognitive functioning during methadone and buprenorphine treatment: Results of a randomized clinical trial (brief report). Soyka, Dec, 699
Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy (letter). Nyhuis, Oct, 593
Bupropion
A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. Evins, Dec, 660
A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder (letter). Weinberger, Oct, 584
A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. Thase, June, 302

C

Cannabinoid blockers
Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial. Soyka, June, 317
Carbamazepine
Clinical experience with carbamazepine overdose: Relationship between serum concentration and neurological severity (letter). Brahmi, April, 241
The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: A nested matched case-control study. Gau, Oct, 509
Card Perseveration Task
Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. Hamidovic, Feb, 45
Catatonia
Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: Case report (letter). Mall, Oct, 572
Catecholamine dysfunction
Catecholamine dysfunction in attention-deficit/hyperactivity disorder: An update. Prince, June, S39
Central nervous system (CNS)
Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H_1 antihistamine: A dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. García-Gea, Dec, 675
Certified registered nurse practitioners
Integrating medical and psychiatric care in patients with bipolar disorder (letter). Fagiolini, April, 257
Children
Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination (letter). Coskun, Dec, 723
Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: An open-label, dose-escalation study (brief report). Findling, Aug, 441
Chronic fatigue syndrome
Successful treatment of chronic fatigue syndrome with duloxetine and trijodthyronine–A case study (letter). Rosenhagen, Feb, 105
Citalopram
Acute pregabalin reversal of citalopram-induced sexual dysfunction in generalized anxiety disorder (letter). Oulis, June, 362
Assessment of the prescription of antidepressant drugs in elderly nursing home patients: A clinical and laboratory follow-up investigation. Chermá, Aug, 424
Citalopram-associated spontaneous ejaculations (letter). Virit, June, 360
Drug-induced liver disease related to citalopram (letter). Neumann, April, 254
Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: A short-term, low-dose, randomized, placebo-controlled study. Altamura, Aug, 406
Clarithromycin
Acute psychosis induced by clarithromycin in a healthy adult? (letter). Kouvelou, Oct, 579
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels. Roerig, Feb, 21
Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29
Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting (brief report). Kilzieh, Feb, 74
Clinical Global Impression (CGI) scale
Confounding influence of extraneous symptoms on Clinical Global Impression ratings for depression (letter). Targum, Oct, 587

© 2008 Lippincott Williams & Wilkins

Clinical Global Impression–Severity (CGI-S) scale
High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes (letter). Mech, April, 240
Clinical Global Impressions-Improvement scale
Tiagabine in adult patients with generalized anxiety disorder: Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. Pollack, June, 308
Clinical Global Impressions of Change (CGI-C) scores
Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29
Clinical trials
Clinical trials of antidepressants: Time to shift to a new model (letter). Katz, Aug, 468
Comments on article by Dr Birkenhager et al "Efficacy of impramine in psychotic versus nonpsychotic depression" (letter). Baldessarini, Dec, 71
Efficacy of imipramine in psychotic versus nonpsychotic depression. Birkenhager, April, 166
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Cutler, April, S20
Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis (brief report). van Nimwegen, April, 214
Reply to Dr Baldessarini's comments on "Efficacy of impramine in psychotic versus nonpsychotic depression" (reply). Birkenhager, Dec, 717
Stimulant dosing in the community treatment of adult attention-deficit/hyperactivity disorder (letter). Olfson, April, 255
Suicidal ideation associated with duloxetine use: A case series (letter). Parikh, Feb, 101
Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia (brief report). Shen, Dec, 691
Venlafaxine for acute heroin detoxification: A double-blind, randomized, control trial. Lin, April, 189
Clomipramine
Half a century of antidepressant drugs: On the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: Tricyclics and tetracyclics (guest editorial). Fangmann, Feb, 1
Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: A short-term, low-dose, randomized, placebo-controlled study. Altamura, Aug, 406
Clonidine
Insomnia, night terror, and depression related to clonidine in attention-deficit/hyperactivity disorder (letter). Ghanizadeh, Dec, 725
Clozapine
A 2-year prospective follow-up study of lower urinary tract symptoms in patients treated with clozapine. Jeong, Dec, 618
A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. Gau, June, 271
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Krakowski, Oct, 485
Augmentation of clozapine's antiagressive properties with lamotrigine in a patient with chronic disorganized schizophrenia (letter). Pavlovic, Feb, 119
Clozapine-induced pericardial effusion (letter). Dauner, Aug, 455
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. Birkenaes, April, 132
Efficacy of lipid-lowering medications in patients treated with clozapine: A naturalistic study (letter). Landry, June, 348
Leukopenia and neutropenia after intoxication with diphenhydramine (nytol) during clozapine treatment (letter). Charbonneau, Dec, 706
Response to clozapine-induced microscopic colitis: A case report and review of the literature (letter). Hawe, Aug, 454
Spontaneous dyskinesia in first-episode psychosis in a Southeast Asian population (brief report). Lee, Oct, 536
Tardive dystonia associated with low-dose of amisulpride: A case report (letter). Sevinçok, Oct, 573
Cocaine dependence
An open-label study of aripiprazole in nonschizophrenic crack-dependent patients (letter). Vorspan, Oct, 570
Quetiapine for the treatment of cocaine dependence: An open-label trial (brief report). Kennedy, April, 221
Cognitive behavioral therapy (CBT)
A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. Evins, Dec, 660
Case report of aripiprazole for persistent developmental stuttering (letter). Tran, Aug, 470
Cognitive functioning
Cognitive functioning during methadone and buprenorphine treatment: Results of a randomized clinical trial (brief report). Soyka, Dec, 699
Cognitive impairment
A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia (brief report). Friedman, Feb, 59
Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: A

© 2008 Lippincott Williams & Wilkins

population-based study. Cancelli, Dec, 654
Efficacy of a nicotine (4 mg)–containing lozenge on the cognitive impairment of nicotine withdrawal. Atzori, Dec, 667
Colitis
Response to clozapine-induced microscopic colitis: A case report and review of the literature (letter). Hawe, Aug, 454
Coma
Clinical experience with carbamazepine overdose: Relationship between serum concentration and neurological severity (letter). Brahmi, April, 241
Comedications
Beyond the "Hype" on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use (guest editorial). de Leon, April, 125
Corticosteroids
Hormonal response to dehydroepiandrosterone administration in schizophrenia: Findings from a randomized, double-blind, placebo-controlled, crossover study (letter). Strous, Aug, 456
CP-101,606
An innovative design to establish proof of concept of the antidepressant effects of NR2B subunit selective *N*-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Preskorn, Dec, 631
Creatinine clearance
Assessment of the prescription of antidepressant drugs in elderly nursing home patients: A clinical and laboratory follow-up investigation. Chermá, Aug, 424
Curcumin
Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer's disease (letter). Baum, Feb, 110
CYP2D6
Effects of the *CYP2D6* gene duplication on the pharmacokinetics and pharmacodynamics of tramadol (brief report). Kirchheiner, Feb, 78
The consequences of 3,4-methylene dioxymethamphetamine induced CYP2D6 inhibition in humans. O'Mathúna, Oct, 525
CYP2D6/CYP3A4
Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms (letter). López-Torres, June, 352
CYP2D6, CYP2C19, CYP2C9
Assessment of the prescription of antidepressant drugs in elderly nursing home patients: A clinical and laboratory follow-up investigation. Chermá, Aug, 424

D

Dehydroepiandrosterone sulfate (DHEAS)
Hormonal response to dehydroepiandrosterone administration in schizophrenia: Findings from a randomized, double-blind, placebo-controlled, crossover study (letter). Strous, Aug, 456
Short-term testosterone augmentation in male schizophrenics: A randomized, duoble-blind, placebo-controlled trial. Ko, Aug, 375
Delusional parasitosis
Second-generation antipsychotics in primary and secondary delusional parasitosis: Outcome and efficacy. Freudenmann, Oct, 500
Dementia Rating Scale (DRS)
Assessment of medication management ability in middle-aged and older adults with bipolar disorder (brief report). Depp, April, 225
Depression, *see also* **Major depressive disorder (MDD); Treatment-resistant depression**
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review. Gao, April, 203
Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies. Thase, Feb, 13
Assessment of the prescription of antidepressant drugs in elderly nursing home patients: A clinical and laboratory follow-up investigation. Chermá, Aug, 424
Clinical trials of antidepressants: Time to shift to a new model (letter). Katz, Aug, 468
Comments on "Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (The BOLDER II Study)" by Dr Thase and colleagues (letters). Rifkin, Dawdy, June, 367
Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: A randomized open-label study. Amsterdam, April, 171
Confounding influence of extraneous symptoms on Clinical Global Impression ratings for depression (letter). Targum, Oct, 587
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: Results of a double-blind, placebo-controlled trial (brief report). Rickels, April, 235
Five female cases of prolonged depression in chronic anorexia nervosa treated with selective estrogen receptor modulator raloxifene-augmented therapy (letter). Yokoyama, Dec, 721
Insomnia, night terror, and depression related to clonidine in attention deficit/hyperctivity disorder (letter). Ghanizadeh, Dec, 725
Myoclonus provoked by lamotrigine in a bipolar patient (letter). Corcuera, April, 248

© 2008 Lippincott Williams & Wilkins

Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy (letter). Nyhuis, Oct, 593
Priming stimulation enhances the effectiveness of low-frequency right prefrontal cortex transcranial magnetic stimulation in major depression. Fitzgerald, Feb, 52
Reply to comments by Dr Rifkin and Dr Dawdy (reply). Thase, June, 368
The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants (brief report). Salkeld, April, 230
Ultrahigh frequency repetitive transcranial magnetic stimulation in unipolar depression (letter). Jakob, Aug, 474

Desmethylcitalopram
Assessment of the prescription of antidepressant drugs in elderly nursing home patients: A cinical and laboratory follow-up investigation. Chermá, Aug, 424

Dextroamphetamine
Methylphenidate for the treatment of apathy in Alzheimer disease: Prediction of response using dextroamphetamine challenge. Herrmann, June, 296

Dextromethorphan
The consequences of 3,4-methylene dioxymethamphetamine induced CYP2D6 inhibition in humans. O'Mathúna, Oct, 525

Diabetes, gestational
Maternal use of antipsychotics in early pregnancy and delivery outcome. Reis, June, 279

Diabetes mellitus (DM)
Scientific standards: Critical comments on the pharmacoepidemiological study of second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia (letter). Cohen, Aug, 461
(reply). Reist, Aug, 462

Dibenzodiazepine
Clozapine-induced pericardial effusion (letter). Dauner, Aug, 455

Didesmethylcitalopram
Assessment of the prescription of antidepressant drugs in elderly nursing home patients: A clinical and laboratory follow-up investigation. Chermá, Aug, 424

Diphenhydramine
Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: A randomized, placebo-controlled trial. Glass, April, 182
Leukopenia and neutropenia after intoxication with diphenhydramine (nytol) during clozapine treatment (letter). Charbonneau, Dec, 706

Disulfiram
Disulfiram-induced punding (letter). Fan, Aug, 473

Divalproex
A case of hyperammonemic encephalopathy after 11 years of valproate therapy (letter). Stewart, June, 361
Divalproex in the treatment of posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial in a veteran population (brief report). Davis, Feb, 84

Dixyrazine
Maternal use of antipsychotics in early pregnancy and delivery outcome. Reis, June, 279

Dopamine
Aripiprazole in a case presenting with Tourette syndrome and obsessive-compulsive disorder (letter). Winter, Aug, 452
Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms (letter). López-Torres, June, 352
Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. Hamidovic, Feb, 45
Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. Wilens, June, S46
Successful treatment of nicotine withdrawal with duloxetine: A case report (letter). Perroud, Feb, 102
Visual and coenesthetic hallucinations associated with modafinil (letter). Oulis, April, 251

Drinking water safety
Water, water everywhere: But is it safe to drink? Return to a muddy topic (editorial). Shader, June, 261

Drug dependence
Successful treatment of nicotine withdrawal with duloxetine: A case report (letter). Perroud, Feb, 102

Drug Effects Questionnaire
Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. Hamidovic, Feb, 45

Drug interactions
Preparation of scientific reports on pharmacokinetic drug interaction studies (editorial). Greenblatt, Aug, 369

Duloxetine
Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function (letter). Ravindran, Feb, 107
Duloxetine-induced cutaneous adverse reaction (letter). Oulis, Feb, 104
Duloxetine treatment of social anxiety disorder with comorbid major depression (letter). Lin, Oct, 591
Reply to comments by Dr Lin (reply). Crippa, Oct, 592
Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. Raskin, Feb, 32
Successful treatment of chronic fatigue syndrome with duloxetine and trijodthyronine–A case study (letter). Rosenhagen, Feb, 105
Successful treatment of nicotine withdrawal with duloxetine: A case report (letter). Perroud, Feb, 102
Suicidal ideation associated with duloxetine use: A case series (letter). Parikh, Feb, 101

Dyskinesia
Oropharyngeal and facial dyskinesia

© 2008 Lippincott Williams & Wilkins

after discontinuation of quetiapine (letter). Kruger, Dec, 705
Spontaneous dyskinesia in first-episode psychosis in a Southeast Asian population (brief report). Lee, Oct, 536
Dyslipidemia
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. Birkenaes, April, 132
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: A case series (letter). Tolliver, Aug, 464
Dysphagia
Antipsychotics and oropharyngeal dysphagia in hospitalized older patients (brief report). Rudolph, Oct, 532
Dysrhythmia
Olanzapine-associated new-onset atrial fibrillation (letter). Waters, June, 354
Dystonia
Acute dystonic reaction after initiating aripiprazole monotherapy in a 20-year-old man (letter). Varkula, April, 245
Tardive dystonia associated with low-dose of amisulpride: A case report. (letter). Sevincok, Oct, 573

E

Edema
Long-acting risperidone–induced periorbital edema (letter). Pelizza, Dec, 709
Editorials
Autism, gut–blood-brain barrier, and mast cells (guest editorial). Theoharides, Oct, 479
Beyond the "Hype" on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use (guest editorial). de Leon, April, 125
Half a century of antidepressant drugs: On the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: Tricyclics and tetracyclics (guest editorial). Fangmann, Feb, 1
Preparation of scientific reports on pharmacokinetic drug interaction studies. Greenblatt, Aug, 369
Some personal reflections on health care reform (editorial). Shader, Dec, 599
Water, water everywhere: But is it safe to drink? Return to a muddy topic (editorial). Shader, June, 261
Editors' Note, June, 263
Ejaculation
Citalopram-associated spontaneous ejaculations (letter). Virit, June, 360
Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: A double-blind, placebo-controlled and randomized study. Safarinejad, Feb, 39
Elderly, *see* **Aging/Aged**
Electroconvulsive therapy (ECT)
Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy (letter). Nyhuis, Oct, 593
Energy balance
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289
Enuresis, nocturnal
Nocturnal enuresis after paroxetine abrupt discontinuation: A case report (letter). Polimeni, Oct, 589
Errata, 123, 624
Erythema multiforme
The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: A nested matched case-control study. Gau, Oct, 509
Escitalopram
Emergence of electric shock-like sensations on escitalopram discontinuation (letter). Prakash, June, 359
Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. Eriksson, April, 195
High-dose escitalopram treatment in patients with obsessive-compulsive disorder: A naturalistic case series (letter). Shim, Feb, 108
Estradiol
Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. Safarinejad, Aug, 418
Extrapyramidal side effects
Acute dystonic reaction after initiating aripiprazole monotherapy in a 20-year-old man (letter). Varkula, April, 245
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review. Gao, April, 203
Predictors for starting depot administration of risperidone in chronic users of antipsychotics. Vehof, Dec, 625
Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia (brief report). Cortese, Feb, 69
Extrapyramidal Symptom Rating Scale (ESRS)
Hormonal response to dehydroepiandrosterone administration in schizophrenia: Findings from a randomized, double-blind, placebo-controlled, crossover study (letter). Strous, Aug, 456
Extrapyramidal symptoms
Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms (letter). López-Torres, June, 352
Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: A disconnect of the striatal D_2 occupancy story: Case report (letter). Shim, June, 353
Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Potkin, April, S4
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in

© 2008 Lippincott Williams & Wilkins

patients with acute exacerbations of schizophrenia. Cutler, April, S20
Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29
Oropharyngeal and facial dyskinesia after discontinuation of quetiapine (letter). Kruger, Dec, 705
Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. Weiden, April, S12
Short-term testosterone augmentation in male schizophrenics: A randomized, double-blind, placebo-controlled trial. Ko, Aug, 375

Extrapyramidal Symptoms Rating Scale (ESRS)
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study (brief report). Emsley, April, 210

F

[^{18}F]Fallypride
Striatal and extrastriatal D_2/D_3-receptor–binding properties of ziprasidone: A positron emission tomography study with [^{18}F]fallypride and [$_{11}$C]raclopride (D_2/D_3-receptor occupancy of ziprasidone). Vernaleken, Dec, 608

Fatigue
Successful treatment of chronic fatigue syndrome with duloxetine and trijodthyronine–A case study (letter). Rosenhagen, Feb, 105

Fibrinogen
Neuroleptic malignant syndrome and the acute phase response (letter). Rosebush, Aug, 459

First-episode psychosis
Predictors of antipsychotic-induced weight gain in first-episode psychosis: Conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Saddichha, Feb, 27
Spontaneous dyskinesia in first-episode psychosis in a Southeast Asian population (brief report). Lee, Oct, 536

First-generation antipsychotics
Predictors for starting depot administration of risperidone in chronic users of antipsychotics. Vehof, Dec, 662
Scientific standards: Critical comments on the pharmacoepidemiological study of second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia (letter). Cohen, Aug, 461
(reply). Reist, Aug, 462
Weight gain and first-generation antipsychotics: Experience from a developing country (letter). Yoon, Oct, 574

Fluoxetine
A double-masked, placebo-controlled study of fluoxetine for hypochondriasis. Fallon, Dec, 638
Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination (letter). Coskun, Dec, 723
Toxic epidermal necrolysis and fluoxetine: A case report (brief report). Jonsson, Feb, 93

Fluvoxamine
Concentration-response relationship for fluvoxamine using remission as an endpoint: A receiver operating characteristics curve analysis in major depression (brief report). Suzuki, June, 325

Follicle-stimulating hormone (FSH)
Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. Safarinejad, Aug, 418

Fracture risk
Fracture risk from psychotropic medications: A population-based analysis. Bolton, Aug, 384
Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. Ziere, Aug, 411

G

Galactorrhea
A case of venlafaxine-induced galactorrhea? (letter). Wichman, Oct, 580

Galantamine
Galantamine as an adjunctive treatment in major depression (letter). Elgamal, June, 357

Gene duplication
Effects of the *CYP2D6* gene duplication on the pharmacokinetics and pharmacodynamics of tramadol (brief report). Kirchheiner, Feb, 78

Generalized anxiety disorder (GAD)
Acute pregabalin reversal of citalopram-induced sexual dysfunction in generalized anxiety disorder (letter). Oulis, June, 362
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: Results of a double-blind, placebo-controlled trial (brief report). Rickels, April, 235
Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study (brief report). Stein, Oct, 561
Rater scoring variability in the serial assessment of anxiety symptoms (letter). Targum, Feb, 118
Tiagabine in adult patients with generalized anxiety disorder: Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. Pollack, June, 308

Gestational diabetes
Maternal use of antipsychotics in early pregnancy and delivery outcome. Reis, June, 279

Ghrelin
A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels. Roerig, Feb, 21
Effect of antipsychotics on peptides involved in energy balance in

© 2008 Lippincott Williams & Wilkins

drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289

Glaucoma

Dose-related increase of intraocular pressure caused by venlafaxine use: Case report (letter). Della Mônica, April, 252

Global Deterioration Scale (GDS)

Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: A population-based study. Cancelli, Dec, 654

Glucose dysregulation

Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine (letter). Weber-Hamann, Oct, 581

Glucose infusion

Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. Chintoh, Oct, 494

Gonadotropin-releasing hormone (GnRH)

Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. Safarinejad, Aug, 418

Go/No-Go Task

Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. Hamidovic, Feb, 45

H

H_1 antihistamine

Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H_1 antihistamine: A dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. García-Gea, Dec, 675

Hallucinations

Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination (letter). Coskun, Dec, 723

Visual and coenesthetic hallucinations associated with modafinil (letter). Oulis, April, 251

Haloperidol

A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. Gau, June, 271

Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Krakowski, Oct, 485

Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia–A case report with a review of the literature (letter). Konopelska, Feb, 120

Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289

Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Potkin, April, S4

Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29

Predictors of antipsychotic-induced weight gain in first-episode psychosis: Conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Saddichha, Feb, 27

HAM-D, *see* Hamilton Depression Rating Scale (HDRS)

Hamilton Anxiety Rating Scale (HAM-A)

Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: Results of a double-blind, placebo-controlled trial (brief report). Rickels, April, 235

Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study (brief report). Stein, Oct, 561

Rater scoring variability in the serial assessment of anxiety symptoms (letter). Targum, Feb, 118

Tiagabine in adult patients with generalized anxiety disorder: Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. Pollack, June, 308

Hamilton Depression Rating Scale (HDRS)

An innovative design to establish proof of concept of the antidepressant effects of NR2B subunit selective *N*-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Preskorn, Dec, 631

Assessment of medication management ability in middle-aged and older adults with bipolar disorder (brief report). Depp, April, 225

Comments on article by Dr Birkenhager et al "Efficacy of impramine in psychotic versus nonpsychotic depression" (letter). Baldessarini, Dec, 716

Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: A randomized open-label study. Amsterdam, April, 171

Efficacy of imipramine in psychotic versus nonpsychotic depression. Birkenhager, April, 166

Galantamine as an adjunctive treatment in major depression (letter). Elgamal, June, 357

Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: A short-term, low-dose, randomized, placebo-controlled study. Altamura, Aug, 406

Methylphenidate and depression (letter). Ng, Feb, 116

Opiate treatment in depression refractory to antidepressants and

© 2008 Lippincott Williams & Wilkins

electroconvulsive therapy (letter). Nyhuis, Oct, 593
Reply to Dr Baldessarini's comments on "Efficacy of impramine in psychotic versus nonpsychotic depression" (reply). Birkenhager, Dec, 717
Reply to Dr Ng's comments on "A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients in patients with treatment-resistant depression" (reply). Pae, Feb, 117

Health care
Some personal reflections on health care reform (editorial). Shader, Dec, 599

Heart rate variability
Influence of olanzapine on QT evariability and complexity measures of heart rate in patients with schizophrenia (brief report). Bär, Dec, 694

Herbal medicine
A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. Yuan, June, 264
Suanzaorentang and serotonin syndrome (letter). Yeung, Feb, 113

Heroin
Venlafaxine for acute heroin detoxification: A double-blind, randomized, control trial. Lin, April, 189

Hormones
Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. Safarinejad, Aug, 418
Hormonal response to dehydroepiandrosterone administration in schizophrenia: Findings from a randomized, double-blind, placebo-controlled, crossover study (letter). Strous, Aug, 456
Short-term testosterone augmentation in male schizophrenics: A randomized, double-blind, placebo-controlled trial. Ko, Aug, 375

Hospital Anxiety and Depression Scale (HADS)
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: Results of a double-blind, placebo-controlled trial (brief report). Rickels, April, 235
Tiagabine in adult patients with generalized anxiety disorder: Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. Pollack, June, 308

Hyperammonemic encephalopathy
A case of hyperammonemic encephalopathy after 11 years of valproate therapy (letter). Stewart, June, 361

Hyperinsulinemic-Euglycemic Clamp
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. Chintoh, Oct, 494

Hyperlipidemia
Efficacy of lipid-lowering medications in patients treated with clozapine: A naturalistic study (letter). Landry, June, 348

Hyperprolactinemia
A case of venlafaxine-induced galactorrhea? (letter). Wichman, Oct, 580
A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. Yuan, June, 264
Antipsychotic-induced hyperprolactinemia: A cross-sectional survey (brief report). Johnsen, Dec, 686
Reply to comments by Dr Peng et al for "Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-action injection" (reply). Bai, Dec, 727

Hypersexuality
Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder? (letter). Schlachetzki, Oct, 567

Hypertension
A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. Thase, June, 302

Hypertriglyceridemia
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: A case series (letter). Tolliver, Aug, 464

Hypochondriasis
A double-masked, placebo-controlled study of fluoxetine for hypochondriasis. Fallon, Dec, 638

Hypoferremia
Neuroleptic malignant syndrome and the acute phase response (letter). Rosebush, Aug, 459

Hypothalamic-pituitary-testis (HPT) axis function
Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. Safarinejad, Aug, 418

Hypothalamus-pituitary-adrenal
Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine (letter). Weber-Hamann, Oct, 581

I

Iloperidone
Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Potkin, April, S4
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Cutler, April, S20
Introduction. Potkin, April, S1

© 2008 Lippincott Williams & Wilkins

Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29
Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. Weiden, April, S12

Imipramine
Efficacy of imipramine in psychotic versus nonpsychotic depression. Birkenhager, April, 166
Comments on article by Dr Birkenhager et al "Efficacy of imipramine in psychotic versus nonpsychotic depression" (letter) Baldessarini, Dec, 716
Reply to Dr Baldessarini's comments on "Efficacy of imipramine in psychotic versus nonpsychotic depression" (reply). Birkenhager, Dec, 717
Half a century of antidepressant drugs: On the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: Tricyclics and tetracyclics (guest editorial). Fangmann, Feb, 1

Impaired sexual function
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR (brief report). Kennedy, June, 329

Impulsivity
Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. Van den Eynde, April, 147

In Memoriam
Frank M. Berger, MD: 1913–2008, Ban, Aug, 374
Albert Hofmann: 1906–2008, Fusar-Poli, Oct, 484

Insertion/deletion polymorphism
Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation (letter). Benedetti, April, 249

Insomnia
Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: A randomized, placebo-controlled trial. Glass, April, 182
Insomnia, night terror, and depression related to clonidine in attention-deficit/hyperactivity disorder (letter). Ghanizadeh, Dec, 725
Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29

Insulin
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289

Insulin resistance
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. Chintoh, Oct, 494

Insulin sensitivity
Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine (letter). Weber-Hamann, Oct, 581

Intellectual and developmental disabilities
Antipsychotic withdrawal–induced relapse predicts future relapses in institutionalized adults with severe intellectual disability. Janowsky, Aug, 401

International Index of Erectile Function (IIEF)
Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: A double-blind, placebo-controlled and randomized study. Safarinejad, Feb, 39

International Prostate Symptom Score (IPSS)
A 2-year prospective follow-up study of lower urinary tract symptoms in patients treated with clozapine. Jeong, Dec, 618

Intraocular pressure
Dose-related increase of intraocular pressure caused by venlafaxine use: Case report (letter). Della Mônica, April, 252

Intravaginal ejaculatory latency time
Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: A double-blind, placebo-controlled and randomized study. Safarinejad, Feb, 39

Irritability
Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: Young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials (letter). Frye, April, 243
Varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline depressive disorder, and methamphetamine abuse in remission (letter). Lyon, Dec, 720

K

"K-hole"
Trapped in the "K-hole": Overview of deaths associated with ketamine misuse in the UK (1993–2006) (letter). Schifano, Feb, 114

Ketamine
Trapped in the "K-hole": Overview of deaths associated with ketamine misuse in the UK (1993–2006) (letter). Schifano, Feb, 114

L

Lamotrigine
Augmentation of clozapine's antiagressive properties with lamotrigine in a patient with chronic disorganized schizophrenia (letter). Pavlovic, Feb, 119
Myoclonus provoked by lamotrigine in a bipolar patient (letter). Corcuera, April, 248

Leptin
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289

Leukopenia
Leukopenia and neutropenia after intoxication with diphenhydramine

© 2008 Lippincott Williams & Wilkins

(nytol) during clozapine treatment (letter). Charbonneau, Dec, 706
Leukopenia during therapy with risperidone long-acting injectable: Two case reports (letter). Uzun, Dec, 713
Lipid-lowering medications
Efficacy of lipid-lowering medications in patients treated with clozapine: A naturalistic study (letter). Landry, June, 348
Lithium
Comparison between lithium and valproate in the treatment of acute mania (letter). Shafti, Dec, 718
Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: A randomized open-label study. Amsterdam, April, 171
Fracture risk from psychotropic medications: A population-based analysis. Bolton, Aug, 384
Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation (letter). Benedetti, April, 249
Maternal use of antipsychotics in early pregnancy and delivery outcome. Reis, June, 279
Liver function tests
Drug-induced liver disease related to citalopram (letter). Neumann, April, 254
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A series of 13 cases, with long-term follow-up (letter). Pittenger, June, 363
Lorazepam
Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: Case report (letter). Mall, Oct, 572
Lower urinary tract symptoms
A 2-year prospective follow-up study of lower urinary tract symptoms in patients treated with clozapine. Jeong, Dec, 618
Luteinizing hormone
Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. Safarinejad, Aug, 418

M

Macroprolactin
Antipsychotic-induced hyperprolactinemia: A cross-sectional survey (brief report). Johnsen, Dec, 686
Magnetic resonance imaging investigation, functional (fMRI)
A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia (brief report). Friedman, Feb, 59
Major depressive disorder (MDD)
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR (brief report). Kennedy, June, 329
An innovative design to establish proof of concept of the antidepressant effects of NR2B subunit selective *N*-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Preskorn, Dec, 631
Confounding influence of extraneous symptoms on Clinical Global Impression ratings for depression (letter). Targum, Oct, 587
Duloxetine treatment of social anxiety disorder with comorbid major depression (letter). Lin, Oct, 591
Galantamine as an adjunctive treatment in major depression (letter). Elgamal, June, 357
Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor–refractory major depressive disorder: A preliminary study (brief report). George, June, 340
Pharmacokinetics of sertraline across pregnancy and postpartum. Freeman, Dec, 646
Priming stimulation enhances the effectiveness of low-frequency right prefrontal cortex transcranial magnetic stimulation in major depression. Fitzgerald, Feb, 52
Reply to comments by Dr Lin (reply). Crippa, Oct, 592
Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. Raskin, Feb, 32
Successful treatment of nicotine withdrawal with duloxetine: A case report (letter). Perroud, Feb, 102
Suicidal ideation associated with duloxetine use: A case series (letter). Parikh, Feb, 101
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. Marcus, April, 156
Varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline depressive disorder, and methamphetamine abuse in remission (letter). Lyon, Dec, 720
Major depressive episode
Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: A randomized open-label study. Amsterdam, April, 171
Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: A short-term, low-dose, randomized, placebo-controlled study. Altamura, Aug, 406
Malaysia
Weight gain and first-generation antipsychotics: Experience from a developing country (letter). Yoon, Oct, 574
Mania
Comparison between lithium and valproate in the treatment of acute mania (letter). Shafti, Dec, 718

© 2008 Lippincott Williams & Wilkins

Ziprasidone-associated mania in Korean schizophrenic patient (letter). Park, Dec, 711
MDD, *see* Major depressive disorder (MDD)
Mecamylamine hydrochloride
Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor–refractory major depressive disorder: A preliminary study (brief report). George, June, 340
Medication Management Ability Assessment (MMAA)
Assessment of medication management ability in middle-aged and older adults with bipolar disorder (brief report). Depp, April, 225
Metabolic syndrome
Beyond the "Hype" on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use (guest editorial). de Leon, April, 125
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. Birkenaes, April, 132
Methadone
Cognitive functioning during methadone and buprenorphine treatment: Results of a randomized clinical trial (brief report). Soyka, Dec, 699
Methamphetamine
Varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline depressive disorder, and methamphetamine abuse in remission (letter). Lyon, Dec, 720
3,4-Methylenedioxymethamphetamine (MDMA)
Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. Kolbrich, Aug, 432
The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. O'Mathúna, Oct, 525
Methylphenidate (MPH)
A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression (reply). Pae, Feb, 117
Catecholamine dysfunction in attention-deficit/hyperactivity disorder: An update. Prince, June, S39
Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: Does chirality matter? Markowitz, June, S54
Does chirality matter? Pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder. Quinn, June, S62
Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. Wilens, June, S46
Introduction. Markowitz, June, S37
Methylphenidate and depression (letter). Ng, Feb, 116
Methylphenidate for the treatment of apathy in Alzheimer disease: Prediction of response using dextroamphetamine challenge. Herrmann, June, 296
Reply to Dr Ng's comments on "A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients in patients with treatment-resistant depression" (reply). Pae, Feb, 117
Stimulant dosing in the community treatment of adult attention-deficit/hyperactivity disorder (letter). Olfson, April, 255
Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination (letter). Coskun, Dec, 723
The effects of methylphenidate on word decoding accuracy in boys with attention-deficit/hyperactivity disorder. (brief report). Bental, Feb, 89
Migration inhibitory factor (MIF)
Autism, gut–blood-brain barrier, and mast cells (guest editorial). Theoharides, Oct, 479
Milnacipran
The Alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Wakeno, Oct, 518
Mini-Mental State Examination Scale (MMSES)
Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: A population-based study. Cancelli, Dec, 654
Methylphenidate for the treatment of apathy in Alzheimer disease: Prediction of response using dextroamphetamine challenge. Herrmann, June, 296
Mirtazapine
Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function (letter). Ravindran, Feb, 107
Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine (letter). Weber-Hamann, Oct, 581
Mirtazapine-induced akathisia (letter). Gulsun, Aug, 467
Modafinil
Visual and coenesthetic hallucinations associated with modafinil (letter). Oulis, April, 251
Modified Overt Aggression Scale
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Krakowski, Oct, 485
Monoamine oxidase inhibitors
Half a century of antidepressant drugs: On the clinical introduction of monoamine oxidase inhibitors,

© 2008 Lippincott Williams & Wilkins

tricyclics, and tetracyclics. Part II: Tricyclics and tetracyclics (guest editorial). Fangmann, Feb, 1

Montgomery-Åsberg Depression Rating Scale (MADRS)
An innovative design to establish proof of concept of the antidepressant effects of NR2B subunit selective *N*-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Preskorn, Dec, 631
Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies. Thase, Feb, 13
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: Results of a double-blind, placebo-controlled trial (brief report). Rickels, April, 235
Priming stimulation enhances the effectiveness of low-frequency right prefrontal cortex transcranial magnetic stimulation in major depression. Fitzgerald, Feb, 52
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. Marcus, April, 156

Mood stabilizer monotherapy
Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: A randomized open-label study. Amsterdam, April, 171

Movement disorders
Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia (brief report). Cortese, Feb, 69

Muscle rigidity
Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29

Myoclonus
Myoclonus provoked by lamotrigine in a bipolar patient (letter). Corcuera, April, 248

N

Naltrexone
Alleviation of both binge eating and sexual dysfunction with naltrexone (letter). Meyer, Dec, 722

Neonates
A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy (brief report). Boucher, June, 334

Neuroleptic malignant syndrome (NMS)
Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: Case report (letter). Mall, Oct, 572
Neuroleptic malignant syndrome and the acute phase response (letter). Rosebush, Aug, 459

Neutropenia
Leukopenia and neutropenia after intoxication with diphenhydramine (nytol) during clozapine treatment (letter). Charbonneau, Dec, 706

Nicotine
Efficacy of a nicotine (4 mg)–containing lozenge on the cognitive impairment of nicotine withdrawal. Atzori, Dec, 667
Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor–refractory major depressive disorder: A preliminary study (brief report). George, June, 340
Successful treatment of nicotine withdrawal with duloxetine: A case report (letter). Perroud, Feb, 102

Nicotine replacement therapy (NRT)
A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. Evins, Dec, 660

Nocturnal enuresis
Nocturnal enuresis after paroxetine abrupt discontinuation: A case report (letter). Polimeni, Oct, 589

Nonpsychotic bipolar I depression
Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies. Thase, Feb, 13
Comments on "Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (The BOLDER II Study)" by Dr Thase and colleagues (letters). Rifkin, Dawdy, June, 367
Reply to comments by Dr Rifkin and Dr Dawdy (reply). Thase, June, 368

Noradrenaline
Successful treatment of nicotine withdrawal with duloxetine: A case report (letter). Perroud, Feb, 102

Nytol, *see* **Diphenhydramine**

O

Obesity, *see also* **Body mass index (BMI); Weight gain**
A preliminary investigation of α-lipoic acid treatment of antipsychotic drug–induced weight gain in patients with schizophrenia. Kim, April, 138
Beyond the "Hype" on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use (guest editorial). de Leon, April, 125
Scientific standards: Critical comments on the pharmacoepidemiological study of second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia (letter). Cohen, Aug, 461
(reply). Reist, Aug, 462

Objective Opioid Withdrawal Scale (OOWS)
Venlafaxine for acute heroin detoxification: A double-blind,

© 2008 Lippincott Williams & Wilkins

randomized, control trial. Lin, April, 189

Obsessive-compulsive disorder (OCD)
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: An open-label switch study (letter). Kim, June, 349
Aripiprazole in a case presenting with Tourette syndrome and obsessive-compulsive disorder (letter). Winter, Aug, 452
High-dose escitalopram treatment in patients with obsessive-compulsive disorder: A naturalistic case series (letter). Shim, Feb, 108
Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: A double-blind, randomized, placebo-controlled study (brief report). Kordon, Oct, 550
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A series of 13 cases, with long-term follow-up (letter). Pittenger, June, 63

Obsessive-compulsive symptoms
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: An open-label switch study (letter). Kim, June, 349
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis (brief report). van Nimwegen, April, 214

Olanzapine
A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels. Roerig, Feb, 21
A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. Gau, June, 271
Atypical antipsychotics and metabolic outcomes in Chinese patients: A comparison of olanzapine and risperidone (letter). Lee, Dec, 707
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Krakowski, Oct, 485
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. Birkenaes, April, 132
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289
Influence of olanzapine on QT variability and complexity measures of heart rate in patients with schizophrenia (brief report). Bär, Dec, 694
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. Chintoh, Oct, 494
Nonfatal suicidal olanzapine intoxication: A case report (letter). Ramos, Oct, 578
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis (brief report). van Nimwegen, April, 214
Olanzapine-associated new-onset atrial fibrillation (letter). Waters, June, 354
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Kinon, Dec, 601
Photo-onycholysis caused by olanzapine and aripiprazole (brief report). Gregoriou, April, 219
Predictors of antipsychotic-induced weight gain in first-episode psychosis: Conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Saddichha, Feb, 27
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study. Kinon, Aug, 392
Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting (brief report). Kilzieh, Feb, 74

Opium cure
Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy (letter). Nyhuis, Oct, 593

Oropharyngeal and facial dyskinesia
Oropharyngeal and facial dyskinesia after discontinuation of quetiapine (letter). Kruger, Dec, 705

Orthostatic dysregulation
Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate (brief report). Langosch, Oct, 555

Osteoporosis
Fracture risk from psychotropic medications: A population-based analysis. Bolton, Aug, 384
Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. Ziere, Aug, 411

Oxcarbazepine
Toxic interaction between valproate and oxcarbazepine: A case detected by the free valproate level (letter). Xiong, Aug, 472

P

Panic disorder
Emergence of electric shock-like sensations on escitalopram discontinuation (letter). Prakash, June, 359

Paranoia
Varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline depressive disorder, and methamphetamine abuse in remission (letter). Lyon, Dec, 720

© 2008 Lippincott Williams & Wilkins

Parkinsonism
Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms (letter). López-Torres, June, 352
Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia (brief report). Cortese, Feb, 69

Paroxetine
Nocturnal enuresis after paroxetine abrupt discontinuation: A case report (letter). Polimeni, Oct, 589

Paroxetine-refractory patients
Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: A double-blind, placebo-controlled and randomized study. Safarinejad, Feb, 39

Pathological jealousy
Low-dose risperidone for pathological jealousy: Report of 3 cases (letter). Bisol, Oct, 595

Peony-Glycyrrhiza Decoction (PGD)
A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. Yuan, June, 264

Pericardial effusion
Clozapine-induced pericardial effusion (letter). Dauner, Aug, 455

Periorbital edema
Long-acting risperidone–induced periorbital edema (letter). Pelizza, Dec, 709

Photo-onycholysis
Photo-onycholysis caused by olanzapine and aripiprazole (brief report). Gregoriou, April, 219

Pindolol
Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: A double-blind, placebo-controlled and randomized study. Safarinejad, Feb, 39

Polymorphism
Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms (letter). López-Torres, June, 352
Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation (letter). Benedetti, April, 249
RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia (brief report). Lane, Feb, 64
The Alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Wakeno, Oct, 518

Polypharmacotherapy
Assessment of the prescription of antidepressant drugs in elderly nursing home patients: A clinical and laboratory follow-up investigation. Chermá, Aug, 424

Positive and Negative Symptoms Scale (PANSS)
The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection: Initial phase 3 studies. (letter). Peng, Dec, 726

Positive and Negative Syndrome Scale–Excited Component (PANSS-EC) score
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Kinon, Dec, 601

Positive and Negative Syndrome Scale (PANSS)
Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Potkin, April, S4
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Cutler, April, S20
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study (brief report). Emsley, April, 210
Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study. Kinon, Aug, 392
Temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials (brief report). Kinon, Oct, 544
Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia (brief report). Shen, Dec, 691

Positron emission tomography (PET)
Striatal and extrastriatal D_2/D_3-receptor–binding properties of ziprasidone: A positron emission tomography study with [^{18}F]fallypride and [$_{11}$C]raclopride (D_2/D_3-receptor occupancy of ziprasidone). Vernaleken, Dec, 608

Postpartum hemorrhage
The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants (brief report). Salkeld, April, 230

Posttraumatic stress disorder (PTSD)
Divalproex in the treatment of posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial in a veteran population (brief report). Davis, Feb, 84
Pregabalin treatment of posttraumatic stress disorder (letter). Strawn, Oct, 596

Pramipexole
Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. Hamidovic, Feb, 45

Pregabalin
Acute pregabalin reversal of citalopram-induced sexual dysfunction in generalized anxiety disorder (letter). Oulis, June, 362
Pregabalin treatment of posttraumatic

© 2008 Lippincott Williams & Wilkins

stress disorder (letter). Strawn, Oct, 596

Pregnancy
A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy (brief report). Boucher, June, 334
Maternal use of antipsychotics in early pregnancy and delivery outcome. Reis, June, 279
Pharmacokinetics of sertraline across pregnancy and postpartum. Freeman, Dec, 646
Recent trends in selective serotonin reuptake inhibitor use in pregnancy (letter). Wichman, Dec, 714
The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants (brief report). Salkeld, April, 230

Premature ejaculation
Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: A double-blind, placebo-controlled and randomized study. Safarinejad, Feb, 39

Premenstrual dysphoric disorder (PMDD)
Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. Eriksson, April, 195

Priming stimulation
Priming stimulation enhances the effectiveness of low-frequency right prefrontal cortex transcranial magnetic stimulation in major depression. Fitzgerald, Feb, 52

Prochlorperazine
Maternal use of antipsychotics in early pregnancy and delivery outcome. Reis, June, 279

Profile of Mood States (POMS)
Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. Hamidovic, Feb, 45

Prolactinoma
Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia–A case report with a review of the literature (letter). Konopelska, Feb, 120

Prolactin
A case of venlafaxine-induced galactorrhea? (letter). Wichman, Oct, 580
A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. Yuan, June, 264
Antipsychotic-induced hyperprolactinemia: A cross-sectional survey (brief report). Johnsen, Dec, 686
Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: A disconnect of the striatal D_2 occupancy story: Case report (letter). Shim, June, 353
Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. Safarinejad, Aug, 418
Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. Weiden, April, S12
The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection (letter). Peng, Dec, 726

Prostaglandin-E_2
Neuroleptic malignant syndrome and the acute phase response (letter). Rosebush, Aug, 459

PRX-00023
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: Results of a double-blind, placebo-controlled trial (brief report). Rickels, April, 235

Psychiatric/psychic symptoms
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Krakowski, Oct, 485
Confounding influence of extraneous symptoms on Clinical Global Impression ratings for depression (letter). Targum, Oct, 587

Psychiatry residents
Teaching psychopharmacology: What works and what doesn't (brief report). Zisook, Feb, 96

Psychopharmacology
Teaching psychopharmacology: What works and what doesn't (brief report). Zisook, Feb, 96

Psychopharmacotherapy
Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: A double-blind, placebo-controlled and randomized study. Safarinejad, Feb, 39

Psychosis, *see also* **Psychotic disorders**
A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. Yuan, June, 264
Acute dystonic reaction after initiating aripiprazole monotherapy in a 20-year-old man (letter). Varkula, April, 245
Acute psychosis induced by clarithromycin in a healthy adult? (letter). Kouvelou, Oct, 579
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study (brief report). Emsley, April, 210
Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis (brief report). van Nimwegen, April, 214

Psychostimulants
Methylphenidate for the treatment of apathy in Alzheimer disease: Prediction of response using

© 2008 Lippincott Williams & Wilkins

dextroamphetamine challenge. Herrmann, June, 296

Psychotic disorders, *see also* **Psychosis**

Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: A 3-month prospective, observational study (letter). Montejo, Oct, 568

Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia–A case report with a review of the literature (letter). Konopelska, Feb, 120

Psychotropic medications

Fracture risk from psychotropic medications: A population-based analysis. Bolton, Aug, 384

Punding

Disulfiram-induced punding (letter). Fan, Aug, 473

PWC

Physician Withdrawal Checklist (PWC-20) (brief report). Rickels, Aug, 447

Q

QTc

Zotepine-induced QTc prolongation (letter). Lin, Oct, 576

QT variability

Influence of olanzapine on QT variability and complexity measures of heart rate in patients with schizophrenia (brief report). Bär, Dec, 694

Quetiapine

A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. Gau, June, 271

Comments on "Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (The BOLDER II Study)" by Dr Thase and colleagues (letters). Rifkin, Dawdy, June, 367

Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. Van den Eynde, April, 147

Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate (brief report). Langosch, Oct, 555

Oropharyngeal and facial dyskinesia after discontinuation of quetiapine (letter). Kruger, Dec, 705

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: A double-blind, randomized, placebo-controlled study (brief report). Kordon, Oct, 550

Quetiapine for the treatment of cocaine dependence: An open-label trial (brief report). Kennedy, April, 221

Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia (brief report). Cortese, Feb, 69

Reply to comments by Dr Rifkin and Dr Dawdy (reply). Thase, June, 368

Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder (letter). Urbano, Dec, 704

R

[^{11}C]Raclopride

Striatal and extrastriatal D_2/D_3-receptor–binding properties of ziprasidone: A positron emission tomography study with [^{18}F]fallypride and [$_{11}$C]raclopride (D_2/D_3-receptor occupancy of ziprasidone). Vernaleken, Dec, 608

Raloxifene

Five female cases of prolonged depression in chronic anorexia nervosa treated with selective estrogen receptor modulator raloxifene-augmented therapy (letter). Yokoyama, Dec, 721

Rapid-cycling bipolar disorder

Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate (brief report). Langosch, Oct, 555

Reading disorder

The effects of methylphenidate on word decoding accuracy in boys with attention-deficit/hyperactivity disorder (brief report). Bental, Feb, 89

Receiver operating characteristics (ROC) curve analysis

Concentration-response relationship for fluvoxamine using remission as an endpoint: A receiver operating characteristics curve analysis in major depression (brief report). Suzuki, June, 325

Resistin

Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289

Restless legs syndrome (RLS)

Mirtazapine-induced akathisia (letter). Gulsun, Aug, 467

Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder (letter). Urbano, Dec, 704

***RGS4* polymorphisms**

RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia (brief report). Lane, Feb, 64

Riluzole

Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A series of 13 cases, with long-term follow-up (letter). Pittenger, June, 363

Rimonabant

Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial. Soyka, June, 317

Risperidone

A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels. Roerig, Feb, 21

© 2008 Lippincott Williams & Wilkins

A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. Gau, June, 271
A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. Yuan, June, 264
Atypical antipsychotics and metabolic outcomes in Chinese patients: A comparison of olanzapine and risperidone (letter). Lee, Dec, 707
Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: Case report (letter). Mall, Oct, 572
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289
Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Potkin, April, S4
Low-dose risperidone for pathological jealousy: Report of 3 cases (letter). Bisol, Oct, 595
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis (brief report). van Nimwegen, April, 214
Predictors of antipsychotic-induced weight gain in first-episode psychosis: Conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Saddichha, Feb, 27
Reply to comments by Dr Peng et al for "Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to respiridone long-acting injection" (reply). Bai, Dec, 727
RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia (brief report). Lane, Feb, 64
Risperidone treatment of borderline personality disorder assessed by a borderline personality disorder–specific outcome measure: A pilot study (letter). Friedel, June, 345
Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting (brief report). Kilzieh, Feb, 74

Risperidone long-acting injection
Leukopenia during therapy with risperidone long-acting injectable: Two case reports (letter). Uzun, Dec, 713
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study (brief report). Emsley, April, 210
Long-acting risperidone–induced periorbital edema (letter). Pelizza, Dec, 709
Predictors for starting depot administration of risperidone in chronic users of antipsychotics. Vehof, Dec, 625
Reply to comments by Dr Peng et al for "Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection" (reply). Bai, Dec, 727
The disparity of pharmacokinetics and prolactin study for risperidone to risperidone long-acting injection (letter). Peng, Dec, 726

Ropinirole
Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder (letter). Urbano, Dec, 704

S

SALSEX total score
Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: A 3-month prospective, observational study (letter). Montejo, Oct, 568

Salute to Our Reviewers, Dec, 730

Schizoaffective disorder
Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder? (letter). Schlachetzki, Oct, 567
Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: A 3-month prospective, observational study (letter). Montejo, Oct, 568
Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type (letter). Weinberger, April, 247
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study. Kinon, Aug, 392

Schizophrenia
A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. Gau, June, 271
A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia (brief report). Friedman, Feb, 59
A preliminary investigation of α-lipoic acid treatment of antipsychotic drug–induced weight gain in patients with schizophrenia. Kim, April, 138
A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. Yuan, June, 264
A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with

© 2008 Lippincott Williams & Wilkins

schizophrenia: Add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering (brief report). Takeuchi, Oct, 540
A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia (brief report). Friedman, Feb, 59
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: An open-label switch study (letter). Kim, June, 349
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review. Gao, April, 203
Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder? (letter). Schlachetzki, Oct, 567
Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: A disconnect of the striatal D_2 occupancy story: Case report (letter). Shim, June, 353
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Krakowski, Oct, 485
Augmentation of clozapine's antiagressive properties with lamotrigine in a patient with chronic disorganized schizophrenia (letter). Pavlovic, Feb, 119
Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: A 3-month prospective, observational study (letter). Montejo, Oct, 568
Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia–A case report with a review of the literature (letter). Konopelska, Feb, 120
Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Potkin, April, S4
Efficacy of lipid-lowering medications in patients treated with clozapine: A naturalistic study (letter). Landry, June, 348
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Cutler, April, S20
Hormonal response to dehydroepiandrosterone administration in schizophrenia: Findings from a randomized, double-blind, placebo-controlled, crossover study (letter). Strous, Aug, 456
Introduction. Potkin, April, S1
Influence of olanzapine on QT variability and complexity measures of heart rate in patients with schizophrenia (brief report). Bär, Dec, 694
Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Kinon, Dec, 601
Predictors of antipsychotic-induced weight gain in first-episode psychosis: Conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Saddichha, Feb, 27
Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia (brief report). Cortese, Feb, 69
Reply to comments by Dr Peng et al for "Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection" (reply). Bai, Dec, 727
RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia (brief report). Lane, Feb, 64
Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. Weiden, April, S12
Scientific standards: Critical comments on the pharmacoepidemiological study of second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia (letter). Cohen, Aug, 461
(reply). Reist, Aug, 462
Short-term testosterone augmentation in male schizophrenics: A randomized, double-blind, placebo-controlled trial. Ko, Aug, 375
Spontaneous dyskinesia in first-episode psychosis in a Southeast Asian population (brief report). Lee, Oct, 536
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study. Kinon, Aug, 392
Striatal and extrastriatal D_2/D_3-receptor–binding properties of ziprasidone: A positron emission tomography study with [^{18}F]fallypride and [$_{11}$C]raclopride (D_2/D_3-receptor occupancy of ziprasidone). Vernaleken, Dec, 608
Temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials (brief report). Kinon, Oct, 544
Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting (brief report). Kilzieh, Feb, 74
Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: An open-label, dose-escalation study (brief report). Findling, Aug, 441

© 2008 Lippincott Williams & Wilkins

Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia (brief report). Shen, Dec, 691
Weight gain and first-generation antipsychotics: Experience from a developing country (letter). Yoon, Oct, 574
Ziprasidone-associated mania in Korean schizophrenic patient (letter). Park, Dec, 711

Second-generation antipsychotics (SGAs), *see also* **Antipsychotics**
A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. Gau, June, 271
A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia (brief report). Friedman, Feb, 59
Predictors for starting depot administration of risperidone in chronic users of antipsychotics. Vehof, Dec, 625
Quetiapine for the treatment of cocaine dependence: An open-label trial (brief report). Kennedy, April, 221
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: A case series (letter). Tolliver, Aug, 464
Scientific standards: Critical comments on the pharmacoepidemiological study of second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia (letter). Cohen, Aug, 461
(reply). Reist, Aug, 462
Second-generation antipsychotics in primary and secondary delusional parasitosis: Outcome and efficacy. Freudenmann, Oct, 500
Weight gain and first-generation antipsychotics: Experience from a developing country (letter). Yoon, Oct, 574
Zotepine-induced QTc prolongation (letter). Lin, Oct, 576

Sedation
Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate (brief report). Langosch, Oct, 555

Seizures
Clinical experience with carbamazepine overdose: Relationship between serum concentration and neurological severity (letter). Brahmi, April, 241

Selective estrogen receptor modulators (SERMs)
Five female cases of prolonged depression in chronic anorexia nervosa treated with selective estrogen receptor modulator raloxifene-augmented therapy (letter). Yokoyama, Dec, 721

Selective serotonin and norepinephrine reuptake inhibitors (SSNRIs)
Duloxetine-induced cutaneous adverse reaction (letter). Oulis, Feb, 104
Duloxetine treatment of social anxiety disorder with comorbid major depression (letter). Lin, Oct, 591
Reply to comments by Dr Lin (reply). Crippa, Oct, 592

Selective serotonin reuptake inhibitors (SSRIs)
An innovative design to establish proof of concept of the antidepressant effects of NR2B subunit selective *N*-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Preskorn, Dec, 631
Assessment of the prescription of antidepressant drugs in elderly nursing home patients: A clinical and laboratory follow-up investigation. Chermá, Aug, 424
Citalopram-associated spontaneous ejaculations (letter). Virit, June, 360
Clinical trials of antidepressants: Time to shift to a new model (letter). Katz, Aug, 468
Concentration-response relationship for fluvoxamine using remission as an endpoint: A receiver operating characteristics curve analysis in major depression (brief report). Suzuki, June, 325
Dose-related increase of intraocular pressure caused by venlafaxine use: Case report (letter). Della Mônica, April, 252
Drug-induced liver disease related to citalopram (letter). Neumann, April, 254
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: Results of a double-blind, placebo-controlled trial (brief report). Rickels, April, 235
Emergence of electric shock-like sensations on escitalopram discontinuation (letter). Prakash, June, 359
Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. Eriksson, April, 195
Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. Safarinejad, Aug, 418
Fracture risk from psychotropic medications: A population-based analysis. Bolton, Aug, 384
Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: A short-term, low-dose, randomized, placebo-controlled study. Altamura, Aug, 406
Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor–refractory major depressive disorder: A preliminary study (brief report). George, June, 340

© 2008 Lippincott Williams & Wilkins

Nocturnal enuresis after paroxetine abrupt discontinuation: A case report (letter). Polimeni, Oct, 589
Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: A double-blind, placebo-controlled and randomized study. Safarinejad, Feb, 39
Recent trends in selective serotonin reuptake inhibitor use in pregnancy (letter). Wichman, Dec, 714
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A series of 13 cases, with long-term follow-up (letter). Pittenger, June, 363
Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. Ziere, Aug, 411
SSRI-induced violent suicide: Does forensic toxicology hold the answer? (letter). Carlin Jr, Aug, 476
Reply to comments by Mr Carlin and Mr Hardisty (reply). Fazel, Aug, 477
The Alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Wakeno, Oct, 518
The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants (brief report). Salkeld, April, 230
Toxic epidermal necrolysis and fluoxetine: A case report (brief report). Jonsson, Feb, 93

Serotonin norepinephrine reuptake inhibitors (SNRIs)
Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. Van den Eynde, April, 147
The Alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Wakeno, Oct, 518
Venlafaxine for acute heroin detoxification: A double-blind, randomized, control trial. Lin, April, 189

Serotonin receptor polymorphisms
Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms (letter). López-Torres, June, 352

Serotonin reuptake inhibitors (SRIs)
Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder (brief report). Kordon, Oct, 550

Serotonin syndrome (SS)
Suanzaorentang and serotonin syndrome (letter). Yeung, Feb, 113

Sertraline
Pharmacokinetics of sertraline across pregnancy and postpartum. Freeman, Dec, 646

Severe mental illness
Beyond the "Hype" on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use (guest editorial). de Leon, April, 125

Sex effects scale
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR (brief report). Kennedy, June, 329

Sexual dysfunction
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR (brief report). Kennedy, June, 329
Alleviation of both binge eating and sexual dysfunction with naltrexone (letter). Meyer, Dec, 722
Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: A 3-month prospective, observational study (letter). Montejo, Oct, 568
Citalopram-associated spontaneous ejaculations (letter). Virit, June, 360
Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function (letter). Ravindran, Feb, 107
Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. Safarinejad, Aug, 418

Sheehan Disability Scale
Tiagabine in adult patients with generalized anxiety disorder: Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. Pollack, June, 308

Skin
The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: A nested matched case-control study. Gau, Oct, 509
Toxic epidermal necrolysis and fluoxetine: A case report (brief report). Jonsson, Feb, 93

Sleep deprivation
Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation (letter). Benedetti, April, 249

Sleep disorder
Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: A randomized, placebo-controlled trial. Glass, April, 182

Sleeping pill
Suanzaorentang and serotonin syndrome (letter). Yeung, Feb, 113

Smoking
A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. Evins, Dec, 660
A preliminary study of sustained-release bupropion for

© 2008 Lippincott Williams & Wilkins

smoking cessation in bipolar disorder (letter). Weinberger, Oct, 584
Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type (letter). Weinberger, April, 247
Efficacy of a nicotine (4 mg)–containing lozenge on the cognitive impairment of nicotine withdrawal. Atzori, Dec, 147
Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor–refractory major depressive disorder: A preliminary study (brief report). George, June, 340
Successful treatment of nicotine withdrawal with duloxetine: A case report (letter). Perroud, Feb, 102
Varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline depressive disorder, and methamphetamine abuse in remission (letter). Lyon, Dec, 720

Social anxiety disorder
Duloxetine treatment of social anxiety disorder with comorbid major depression (letter). Lin, Oct, 591
Reply to comments by Dr Lin (reply). Crippa, Oct, 592

Social Phobia Inventory (SPIN)
Duloxetine treatment of social anxiety disorder with comorbid major depression (letter). Lin, Oct, 591
Reply to comments by Dr Lin (reply). Crippa, Oct, 592

Sodium valproate
Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate (brief report). Langosch, Oct, 555

Speech therapy
Case report of aripiprazole for persistent developmental stuttering (letter). Tran, Aug, 470

Spironolactone
No effect of spironolactone on bulimia nervosa symptoms (letter). von Wietersheim, April, 258

Stevens-Johnson syndrome (SJS)
The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: A nested matched case-control study. Gau, Oct, 509

Stimulant dosing
Stimulant dosing in the community treatment of adult attention-deficit/hyperactivity disorder (letter). Olfson, April, 255

Stuttering
Case report of aripiprazole for persistent developmental stuttering (letter). Tran, Aug, 470

Suanzaorentang
Suanzaorentang and serotonin syndrome (letter). Yeung, Feb, 113

Subacute liver dystrophy
Drug-induced liver disease related to citalopram (letter). Neumann, April, 254

Substance abuse deaths
Trapped in the "K-hole": Overview of deaths associated with ketamine misuse in the UK (1993–2006) (letter). Schifano, Feb, 114

Substance abuse disorders
Quetiapine for the treatment of cocaine dependence: An open-label trial (brief report). Kennedy, April, 221

Substance use
An open-label study of aripiprazole in nonschizophrenic crack-dependent patients (letter). Vorspan, Oct, 570
Beyond the "Hype" on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use (guest editorial). de Leon, April, 125
Venlafaxine for acute heroin detoxification: A double-blind, randomized, control trial. Lin, April, 189

Suicidal ideation
Comments on article by Dr Birkenhager et al "Efficacy of imipramine in psychotic versus nonpsychotic" depression (letter). Baldessarini, Dec 716
Efficacy of imipramine in psychotic versus nonpsychotic depression. Birkenhager, April, 166
Reply to Dr Baldessarini comments of impramine comments on "Efficacy of imipramine in psychotic versus nonpsychotic depression" (reply). Birkenhager, Dec, 717

Suicide
Nonfatal suicidal olanzapine intoxication: A case report (letter). Ramos, Oct, 578
Reply to comments by Mr Carlin and Mr Hardisty (reply). Fazel, Aug, 477
SSRI-induced violent suicide: Does forensic toxicology hold the answer? (letter). Carlin Jr, Aug, 476

Suspicion, extreme
Low-dose risperidone for pathological jealousy: Report of 3 cases (letter). Bisol, Oct, 595

Sweating
Antidepressant-induced sweating alleviated by aripiprazole (letter). Lu, Dec, 710

T

Taiwan
A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. Gau, June, 271

Tardive dyskinesia (TD)
Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia: A case report (brief report). Cortese, Feb, 69

Tardive dystonia
Tardive dystonia associated with low-dose of amisulpride (letter). Sevincok, Oct, 573

Temazepam
Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: A randomized, placebo-controlled trial. Glass, April, 182

© 2008 Lippincott Williams & Wilkins

Testosterone
Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male exual dysfunction. Safarinejad, Aug, 418
Short-term testosterone augmentation in male schizophrenics: A randomized, double-blind, placebo-controlled trial. Ko, Aug, 375
Thriomax, *see* **Clarithromycin**
Tiagabine
Tiagabine in adult patients with generalized anxiety disorder: Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. Pollack, June, 308
Tobacco deprivation, *see also* **Nicotine; Smoking**
Efficacy of a nicotine (4 mg)–containing lozenge on the cognitive impairment of nicotine withdrawal. Atzori, Dec, 667
Topiramate
Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type (letter). Weinberger, April, 247
Topiramate treatment of women with borderline personality disorder, part II: An open 18-month follow-up (letter). Loew, June, 355
Total sleep deprivation
Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation (letter). Benedetti, April, 249
Tourette syndrome
Aripiprazole in a case presenting with Tourette syndrome and obsessive-compulsive disorder (letter). Winter, Aug, 452
Toxic epidermal necrolysis (TEN)
The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: A nested matched case-control study. Gau, Oct, 509
Toxic epidermal necrolysis and fluoxetine: A case report (brief report). Jonsson, Feb, 93
Tramadol
Effects of the *CYP2D6* gene duplication on the pharmacokinetics and pharmacodynamics of tramadol (brief report). Kirchheiner, Feb, 78
Transcranial magnetic stimulation, repetitive (rTMS)
Priming stimulation enhances the effectiveness of low-frequency right prefrontal cortex transcranial magnetic stimulation in major depression. Fitzgerald, Feb, 52
Ultrahigh frequency repetitive transcranial magnetic stimulation in unipolar depression (letter). Jakob, Aug, 474
Treatment discontinuation
Temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials (brief report). Kinon, Oct, 544
Treatment-resistant depression
A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression (reply). Pae, Feb, 117
Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function (letter). Ravindran, Feb, 107
Comments on article by Dr Birkenhager et al "Efficacy of imipramine in psychotic versus nonpsychotic depression" (letter). Baldessarini, Dec 716
Efficacy of imipramine in psychotic versus nonpsychotic depression. Birkenhager, April, 166
Methylphenidate and depression (letter). Ng, Feb, 116
Priming stimulation enhances the effectiveness of low-frequency right prefrontal cortex transcranial magnetic stimulation in major depression. Fitzgerald, Feb, 52
Reply to Dr Baldessarini comments of impramine comments on "Efficacy of imipramine in psychotic versus nonpsychotic depression" (reply). Birkenhager, Dec, 717
Reply to Dr Ng's comments on "A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients in patients with treatment-resistant depression" (reply). Pae, Feb, 117
Tremor
Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Kane, April, S29
Tricyclic antidepressants (TCAs)
Half a century of antidepressant drugs: On the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: Tricyclics and tetracyclics (guest editorial). Fangmann, Feb, 1
Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine (letter). Weber-Hamann, Oct, 581
Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy (letter). Nyhuis, Oct, 593
Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. Ziere, Aug, 411
Suicidal ideation associated with duloxetine use: A case series (letter). Parikh, Feb, 101
Tricyclics and tetracyclics
Half a century of antidepressant drugs: On the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: Tricyclics and tetracyclics (guest editorial). Fangmann, Feb, 1

© 2008 Lippincott Williams & Wilkins

Triglycerides
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: A case series (letter). Tolliver, Aug, 464

Trijodthyronine
Successful treatment of chronic fatigue syndrome with duloxetine and trijodthyronine–A case study (letter). Rosenhagen, Feb, 105

U

Unipolar depressive disorder
A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. Evins, Dec, 660

V

Valproate
A case of hyperammonemic encephalopathy after 11 years of valproate therapy (letter). Stewart, June, 361
Comparison between lithium and valproate in the treatment of acute mania (letter). Shafti, Dec, 718
Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate (brief report). Langosch, Oct, 555
The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: A nested matched case-control study. Gau, Oct, 509
Toxic interaction between valproate and oxcarbazepine: A case detected by the free valproate level (letter). Xiong, Aug, 472

Varenicline
Varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline depressive disorder, and methamphetamine abuse in remission (letter). Lyon, Dec, 720

Venlafaxine
A case of venlafaxine-induced galactorrhea? (letter). Wichman, Oct, 580
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR (brief report). Kennedy, June, 329
Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: A randomized open-label study. Amsterdam, April, 171
Dose-related increase of intraocular pressure caused by venlafaxine use: Case report (letter). Della Mônica, April, 252
Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine (letter). Weber-Hamann, Oct, 581
Venlafaxine for acute heroin detoxification: A double-blind, randomized, control trial. Lin, April, 189

Ventricular septal defects
Recent trends in selective serotonin reuptake inhibitor use in pregnancy (letter). Wichman, Dec, 714

Videofluoroscopic swallow study (VFSS)
Antipsychotics and oropharyngeal dysphagia in hospitalized older patients (brief report). Rudolph, Oct, 532

Visfatin
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289

Visual Analogue Scale (VAS)
Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation (letter). Benedetti, April, 249

W

Water contamination
Water, water everywhere: But is it safe to drink? Return to a muddy topic (editorial). Shader, June, 261

Weight gain
A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels. Roerig, Feb, 21
A preliminary investigation of α-lipoic acid treatment of antipsychotic drug–induced weight gain in patients with schizophrenia. Kim, April, 138
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. Birkenaes, April, 132
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias, June, 289
Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate (brief report). Langosch, Oct, 555
Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine (letter). Weber-Hamann, Oct, 581
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. Chintoh, Oct, 494
Predictors of antipsychotic-induced weight gain in first-episode psychosis: Conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Saddichha, Feb, 27
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: A case series (letter). Tolliver, Aug, 464
Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. Weiden, April, S12

© 2008 Lippincott Williams & Wilkins

Weight gain and first-generation antipsychotics: Experience from a developing country (letter). Yoon, Oct, 574

Withdrawal

Antipsychotic withdrawal–induced relapse predicts future relapses in institutionalized adults with severe intellectual disability. Janowsky, Aug, 401

Efficacy of a nicotine (4 mg)–containing lozenge on the cognitive impairment of nicotine withdrawal. Atzori, Dec, 667

Nocturnal enuresis after paroxetine abrupt discontinuation: A case report (letter). Polimeni, Oct, 589

Physician Withdrawal Checklist (PWC-20) (brief report). Rickels, Aug, 447

Successful treatment of nicotine withdrawal with duloxetine: A case report (letter). Perroud, Feb, 102

Venlafaxine for acute heroin detoxification: A double-blind, randomized, control trial. Lin, April, 189

Women

A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy (brief report). Boucher, June, 334

Maternal use of antipsychotics in early pregnancy and delivery outcome. Reis, June, 279

Pharmacokinetics of sertraline across pregnancy and postpartum. Freeman, Dec, 646

Topiramate treatment of women with borderline personality disorder, part II: An open 18-month follow-up (letter). Loew, June, 355

Y

Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: An open-label switch study (letter). Kim, June, 349

Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis (brief report). van Nimwegen, April, 214

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: A double-blind, randomized, placebo-controlled study (brief report). Kordon, Oct, 550

Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A series of 13 cases, with long-term follow-up (letter). Pittenger, June, 363

Young Mania Rating Scale (YMRS)

Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: Young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials (letter). Frye, April, 243

High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes (letter). Mech, April, 240

Z

Ziprasidone

Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: A 3-month prospective, observational study (letter). Montejo, Oct, 568

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Cutler, April, S20

High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes (letter). Mech, April, 240

Striatal and extrastriatal D_2/D_3-receptorbinding properties of ziprasidone: A positron emission tomography study with [^{18}F]fallypride and [$_{11}$C]raclopride (D_2/D_3-receptor occupancy of ziprasidone). Vernaleken, Dec, 674

Ziprasidone-associated mania in Korean schizophrenic patient (letter). Park, Dec, 711

Zotepine

A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. Gau, June, 271

Zotepine-induced QTc prolongation (letter). Lin, Oct, 576

Zyprexa, *see* Olanzapine

© 2008 Lippincott Williams & Wilkins